51
|
Chen J, Lin Y, Li T, Zhu H, Huang F, Yang C, Guo F. Calorie restriction on normal body weight mice prevents body weight regain on a follow-up high-fat diet by shaping an obesity-resistant-like gut microbiota profile. Food Funct 2022; 13:7684-7696. [PMID: 35735100 DOI: 10.1039/d1fo04358g] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Calorie restriction (CR) is one of the most common approaches for obesity treatment, but whether resuming ad libitum feeding after CR in normal-weight mice can affect excessive weight regain remains poorly studied. To address this issue, male C57BL/6 mice were placed in three groups: a control group (n = 10), a group fed normal diet with 30% CR (n = 20); and a group fed a HF diet (n = 30). After four weeks, the CR group was fed either a normal diet (NDCR, n = 10) or a high-fat diet (HFCR, n = 10) for an additional eight weeks. At the end of the experiment, mice in the HF group ranked in the upper and lower thirds for weight gain were designated as obesity-prone (HFOP, n = 10) and obesity-resistant (HFOR, n = 10), respectively. CR delayed weight regain and visceral fat accumulation. Gut microbiota in the HFCR group were more similar to the HFOR group than the HFOP group, mainly due to reversion of the decreased level of Clostridiales induced by CR. Mediation analysis showed that Clostridiales may delay body weight regain by affecting the interconversion of succinate and fumarate. Random forest and structural equation analyses showed Christensenellaceae were the most important biomarker for alleviation of obesity. In conclusion, CR shapes an obesity-resistant-like gut microbiota profile that may attenuate body weight regain.
Collapse
Affiliation(s)
- Jiedong Chen
- Department of Nutrition and Food Safety, School of Public Health, Fujian Medical University, FuZhou 350122, P.R. China.
| | - Yiqi Lin
- Department of Nutrition and Food Safety, School of Public Health, Fujian Medical University, FuZhou 350122, P.R. China.
| | - Tong Li
- Department of Nutrition and Food Safety, School of Public Health, Fujian Medical University, FuZhou 350122, P.R. China.
| | - Hongni Zhu
- Department of Nutrition and Food Safety, School of Public Health, Fujian Medical University, FuZhou 350122, P.R. China.
| | - Fang Huang
- Department of Nutrition and Food Safety, School of Public Health, Fujian Medical University, FuZhou 350122, P.R. China.
| | - Changwei Yang
- Department of Nutrition and Food Safety, School of Public Health, Fujian Medical University, FuZhou 350122, P.R. China.
| | - Fuchuan Guo
- Department of Nutrition and Food Safety, School of Public Health, Fujian Medical University, FuZhou 350122, P.R. China.
| |
Collapse
|
52
|
Yang AM, Lin CY, Liu SH, Syu GD, Sun HJ, Lee KC, Lin HC, Hou MC. Saccharomyces Boulardii Ameliorates Non-alcoholic Steatohepatitis in Mice Induced by a Methionine-Choline-Deficient Diet Through Gut-Liver Axis. Front Microbiol 2022; 13:887728. [PMID: 35814685 PMCID: PMC9260146 DOI: 10.3389/fmicb.2022.887728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Accepted: 05/17/2022] [Indexed: 11/13/2022] Open
Abstract
Non-alcoholic steatohepatitis (NASH) is affecting people worldwide. Changes in the intestinal microbiome are crucial to NASH. A previous study showed that eradicating intestinal fungi ameliorates NASH; however, the role of intestinal fungi in the development of NASH remains unclear. Saccharomyces boulardii (SB), a dietary supplement yeast, has been reported to restore the integrity of the intestine. Here, we tested the effect of SB in the treatment of NASH. For this study, we fed eight-week-old C57/BL6 male mice either a methionine-choline deficient (MCD) diet or a normal chow diet (NCD) for eight weeks. Half of the MCD diet-fed mice were gavaged with SB (5 mg/day) once daily. The remainder of the NCD–fed mice were gavaged with normal saline as a control. The MCD diet-fed mice on SB supplement showed better liver function, less hepatic steatosis, and decreased inflammation. Both hepatic inflammatory gene expression and fibrogenic gene expression were suppressed in mice with SB gavage. Intestinal damage caused by the MCD diet was tampered with, intestine inflammation decreased, and gut permeability improved in mice that had been given the SB supplement. Deep sequencing of the fecal microbiome showed a potentially increased beneficial gut microbiota and increased microbiota diversity in the SB-supplemented mice. The SB supplement maintains gut integrity, increases microbial diversity, and increases the number of potentially beneficial gut microbiota. Thus, the SB supplement attenuates gut leakage and exerts a protective effect against NASH. Our results provide new insight into the prevention of NASH.
Collapse
Affiliation(s)
- An-Ming Yang
- Department of Internal Medicine, En Chu Kong Hospital, New Taipei City, Taiwan
- Department of Nursing, Yuanpei University of Medical Technology, Hsinchu, Taiwan
- *Correspondence: An-Ming Yang,
| | - Chien-Yu Lin
- Department of Internal Medicine, En Chu Kong Hospital, New Taipei City, Taiwan
- School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
| | - Shih-Hao Liu
- Division of Pathology, En Chu Kong Hospital, New Taipei City, Taiwan
| | - Guan-Da Syu
- Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan
- International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan
| | - Hao-Jhe Sun
- Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei City, Taiwan
| | - Kuei-Chuan Lee
- Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei City, Taiwan
- Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan
- Kuei-Chuan Lee,
| | - Han-Chieh Lin
- Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei City, Taiwan
- Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan
| | - Ming-Chih Hou
- Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei City, Taiwan
- Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan
| |
Collapse
|
53
|
Sheu NW, Huang SH, Wu DC, Kao JY, Lin KD. Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus. PLoS One 2022; 17:e0265323. [PMID: 35604898 PMCID: PMC9126384 DOI: 10.1371/journal.pone.0265323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Accepted: 02/21/2022] [Indexed: 11/29/2022] Open
Abstract
Background Helicobacter pylori infection is known to decrease the incidences of autoimmune diseases and inflammatory bowel disease(IBD). Our aim was investigating the effect of H. pylori treatment in diabetes mellitus(DM) patients. Methods Adults with newly-diagnosed H. pylori infection or peptic ulcer disease(PUD) within the general population and DM population were identified from the National Health Insurance Research Database of Taiwan from 2000–2010. 79,181 patients were assigned to the 3 groups: general population with PUD without H. pylori treatment(PUD-HPRx in general population), DM patients with PUD without H. pylori treatment(PUD-HPRx in DM), and DM patients with PUD who received H. pylori treatment(PUD+HPRx in DM). Results Higher incidences of autoimmune diseases and IBD were observed in the PUD+HPRx in DM group than in the PUD-HPRx in general population and PUD-HPRx in DM groups (autoimmune diseases = 5.14% vs 3.47% and 3.65%; IBD = 5.60% vs 3.17% and 3.25%; P<0.0001). A lower all-cause mortality was noted in the PUD+HPRx in DM group (HR: 0.937, P<0.001) than in the PUD-HPRx in DM group. Trends of a higher incidence of IBD and a lower mortality in younger patients in the PUD+HPRx in DM group compared with the PUD-HPRx in DM group were noted. Conclusions The results revealed that H. pylori treatment increased the incidences of autoimmune diseases and IBD and decreased the all-cause mortality in the DM group with PUD. The effect was more significant in younger patients. This finding assists in realizing the influence of H. pylori treatment in the DM population.
Collapse
Affiliation(s)
- Nai-Wei Sheu
- Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | - Shu-Heng Huang
- Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | - Deng-Chyang Wu
- Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - John Y. Kao
- Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, Michigan
| | - Kun-Der Lin
- Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- * E-mail:
| |
Collapse
|
54
|
(20R)-Panaxadiol as a Natural Active Component with Anti-Obesity Effects on ob/ob Mice via Modulating the Gut Microbiota. Molecules 2022; 27:molecules27082502. [PMID: 35458705 PMCID: PMC9032863 DOI: 10.3390/molecules27082502] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 04/01/2022] [Accepted: 04/10/2022] [Indexed: 02/01/2023] Open
Abstract
Obesity is an important cause of diseases such as type 2 diabetes, non-alcoholic fatty liver and atherosclerosis. The use of ingredients extracted from traditional Chinese medicine for weight loss is now receiving more and more attention. Ginseng has been recorded since ancient times for the treatment of diabetes. The (20R)-Panaxadiol (PD) belongs to the ginseng diol type compounds, which are moderately bioavailable and may remain in the intestinal tract for a longer period of time. This study investigated the potential positive effect of PD in ob/ob mice and evaluated its effect against obesity. The ob/ob mice were administered PD for ten weeks. Our study showed that PD could improve obesity, glucose tolerance disorder, as well as gut dysbiosis. Panaxadiol decreased ob/ob mice’s Firmicutes/Bacteroidetes (F/B). Furthermore, 16S rRNA gene sequencing of the fecal microbiota suggested that PD changed the composition of the gut microbiota in ob/ob mice and modulated specific bacteria such as lactobacillus, prevotellace and so on. Moreover, PD improved the intestinal wall integrity. In conclusion, our results suggest that (20R)-Panaxadiol, as an active ingredient of the traditional Chinese medicinal herb ginseng, may improve obesity to some extent via improving gut microbiota
Collapse
|
55
|
Chauhan A, Semwal DK, Semwal RB, Joshi SK, Adhana RK, Goswami MS. Modulation of gut microbiota with Ayurveda diet and lifestyle: A review on its possible way to treat type 2 diabetes. Ayu 2022; 43:35-44. [PMID: 37655174 PMCID: PMC10468021 DOI: 10.4103/ayu.ayu_7_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 07/06/2021] [Accepted: 04/17/2023] [Indexed: 09/02/2023] Open
Abstract
Background The prevalence of type 2 diabetes (T2D) has increased substantially in the past few decades throughout the world. In India, the epidemic of diabetes continues to increase irrespective of area, status, and age. Despite various scientific societies involved in the treatment of diabetes, still, the burden of diabetes keeps growing. Aims The aim of this work is to explore the Ayurvedic concept of a personalized diet to modulate the gut microbiota for the treatment of T2D. Material and methods A thorough study of literature from online scientific databases including Web of Science, PubMed, Scopus, and Google Scholar as well as from classical texts of Ayurveda was done. A careful compilation was done to extract the valuable output of the personalized diet to modulate the gut microbiota. Results There are various diets used to control blood glucose levels, and their effects are also being studied on the transcriptome or epigenome despite 99.9% genomic similarity among human beings. However, microbiomes have only 10% similarity. Ayurvedic diet is given on the basis of Prakriti (body constitution), therefore, it is also called personalized diet. Conclusion The diets prescribed for T2D in Ayurveda are high in fibers, polyphenols, and complex carbohydrates which enrich butyrate-producing bacteria and decrease lipopolysaccharide-producing bacteria. Hence, there is a need to have a personalized diet to manage the glucose level by enriching beneficial gut microbiota. The approach of a personalized diet associated with gut microbiota can be helpful in maintaining blood sugar in T2D patients.
Collapse
Affiliation(s)
- Ashutosh Chauhan
- Department of Biotechnology, Faculty of Biomedical Sciences, Uttarakhand Ayurved University, Dehradun, Uttarakhand, India
| | - Deepak Kumar Semwal
- Department of Phytochemistry, Faculty of Biomedical Sciences, Uttarakhand Ayurved University, Dehradun, Uttarakhand, India
| | - Ruchi Badoni Semwal
- Department of Chemistry, VSKC Government Postgraduate College, Dakpathar, Dehradun, Uttarakhand, India
| | - Sunil Kumar Joshi
- Department of Shalya Tantra, Uttarakhand Ayurved University, Haridwar, Uttarakhand, India
| | - Rajesh Kumar Adhana
- Department of Agad Tantra, Uttarakhand Ayurved University, Dehradun, Uttarakhand, India
| | - Madhavi Sanjay Goswami
- Department of Rachna Sharir, Uttarakhand Ayurved University, Rishikul Campus, Haridwar, Uttarakhand, India
| |
Collapse
|
56
|
Dahiya D, Nigam PS. The Gut Microbiota Influenced by the Intake of Probiotics and Functional Foods with Prebiotics Can Sustain Wellness and Alleviate Certain Ailments like Gut-inflammation and Colon-Cancer. Microorganisms 2022; 10:microorganisms10030665. [PMID: 35336240 PMCID: PMC8954736 DOI: 10.3390/microorganisms10030665] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 03/12/2022] [Accepted: 03/18/2022] [Indexed: 12/14/2022] Open
Abstract
The gut microbiota is composed of several microbial strains, with diverse and variable combinations in healthy and sick persons, changing at different stages of life. A healthy balance between host and gut microorganisms must be maintained in order to perform the normal physiological, metabolic, and immune functions and prevent disease development. Disturbances in the balance of the gut microbiota by diverse reasons initiate several health issues and promote the progression of certain diseases. This review is based on published research and reports that describe the role of probiotic microorganisms in the sustainability of health and the alleviation of certain diseases. Information is presented on the GRAS strains that are used as probiotics in the food industry for the production of fermented milk, yogurt, fermented food, functional foods, and probiotic drinks. To maintain a healthy microbiota, probiotic supplements in the form of freeze-dried live cells of probiotic strains are also available in different forms to consumers. The health benefits of lactic acid bacteria and other microorganisms and their role in the control of certain diseases such as gut inflammation, diabetes, and bowel cancer and in the safeguarding of the gut epithelial permeability from the invasion of pathogens are discussed.
Collapse
Affiliation(s)
- Divakar Dahiya
- Wexham Park Hospital, Wexham Street, Slough SL2 4HL, Berkshire, UK;
| | - Poonam Singh Nigam
- Biomedical Sciences Research Institute, Ulster University, Coleraine BT52 1SA, Northern Ireland, UK
- Correspondence:
| |
Collapse
|
57
|
The next generation beneficial actions of novel probiotics as potential therapeutic targets and prediction tool for metabolic diseases. J Food Drug Anal 2022; 30:1-10. [PMID: 35647717 PMCID: PMC9931004 DOI: 10.38212/2224-6614.3396] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 12/03/2021] [Indexed: 11/18/2022] Open
Abstract
The prevalence of metabolic disease has rising and affected over 1,000 million populations globally. Since the metabolic disease and its related complication are board, it has become the major health hazard of modern world. However, Long term medication of metabolic disease may cause serious side effects and risk for adverse health problems. Recently, emerging studies focus on exploring the mechanistic details of metabolic state in disease development and progression. Gut bacteria ecosystem was considered to play a pivotal role in regulating energy homeostasis and great associated with the development of metabolic disease. Accumulated evidences indicated that Akkermansia muciniphila, Faecalibacterium prausnitzii, and Roseburia hominis improve the balance of the microecology in the intestine of the host and have positive effects on enhancing nutrients absorption. Hence, the novel probiotics as therapeutic target to modify gut microbiota generally focus on improving microbiota dysbiosis, and offers new prospects for treating metabolic disease. In the present review, we discuss the significant roles and regulatory properties of specific bacterium in the context of intestinal microbial balance, explores the kinds of harmful/beneficial bacteria that were likely to act as indicator for metabolic disease. Further proposed a stepwise procedure in the basis of sequencing technology with that of innovative option to reestablish the microbial equilibrium and prevent metabolic disease.
Collapse
|
58
|
Tresserra-Rimbau A, Castro-Barquero S, Becerra-Tomás N, Babio N, Martínez-González MÁ, Corella D, Fitó M, Romaguera D, Vioque J, Alonso-Gomez AM, Wärnberg J, Martínez JA, Serra-Majem L, Estruch R, Tinahones FJ, Lapetra J, Pintó X, Tur JA, López-Miranda J, Cano-Ibáñez N, Delgado-Rodríguez M, Matía-Martín P, Daimiel L, Martín Sánchez V, Vidal J, Vázquez C, Ros E, Basterra FJ, Fernández de la Puente M, Asensio EM, Castañer O, Bullón-Vela V, Tojal-Sierra L, Gómez-Gracia E, Cases-Pérez E, Konieczna J, García-Ríos A, Casañas-Quintana T, Bernal-Lopez MR, Santos-Lozano JM, Esteve-Luque V, Bouzas C, Vázquez-Ruiz Z, Palau-Galindo A, Barragan R, López Grau M, Razquín C, Goicolea-Güemez L, Toledo E, Vergaz MV, Lamuela-Raventós RM, Salas-Salvadó J. Adopting a High-Polyphenolic Diet Is Associated with an Improved Glucose Profile: Prospective Analysis within the PREDIMED-Plus Trial. Antioxidants (Basel) 2022; 11:antiox11020316. [PMID: 35204199 PMCID: PMC8868059 DOI: 10.3390/antiox11020316] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 01/30/2022] [Accepted: 02/01/2022] [Indexed: 02/05/2023] Open
Abstract
Previous studies suggested that dietary polyphenols could reduce the incidence and complications of type-2 diabetes (T2D); although the evidence is still limited and inconsistent. This work analyzes whether changing to a diet with a higher polyphenolic content is associated with an improved glucose profile. At baseline, and at 1 year of follow-up visits, 5921 participants (mean age 65.0 ± 4.9, 48.2% women) who had overweight/obesity and metabolic syndrome filled out a validated 143-item semi-quantitative food frequency questionnaire (FFQ), from which polyphenol intakes were calculated. Energy-adjusted total polyphenols and subclasses were categorized in tertiles of changes. Linear mixed-effect models with random intercepts (the recruitment centers) were used to assess associations between changes in polyphenol subclasses intake and 1-year plasma glucose or glycosylated hemoglobin (HbA1c) levels. Increments in total polyphenol intake and some classes were inversely associated with better glucose levels and HbA1c after one year of follow-up. These associations were modified when the analyses were run considering diabetes status separately. To our knowledge, this is the first study to assess the relationship between changes in the intake of all polyphenolic groups and T2D-related parameters in a senior population with T2D or at high-risk of developing T2D.
Collapse
Affiliation(s)
- Anna Tresserra-Rimbau
- Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, 08921 Barcelona, Spain;
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Correspondence:
| | - Sara Castro-Barquero
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Nerea Becerra-Tomás
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
| | - Nancy Babio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
| | - Miguel Ángel Martínez-González
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Dolores Corella
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Montserrat Fitó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Dora Romaguera
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
| | - Jesús Vioque
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Alicante Institute for Health and Biomedical Research, University Miguel Hernandez (ISABIAL-UMH), 03010 Alicante, Spain
| | - Angel M. Alonso-Gomez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Julia Wärnberg
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nursing, Institute of Biomedical Research in Málaga (IBIMA), University of Málaga, 29010 Malaga, Spain
| | - José Alfredo Martínez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
- Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
| | - Luís Serra-Majem
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, 35016 Las Palmas de Gran Canaria, Spain
| | - Ramon Estruch
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Francisco J. Tinahones
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Regional University Hospital of Malaga, Instituto de Investigación Biomédica de Malaga (IBIMA), University of Malaga, 29010 Malaga, Spain
| | - José Lapetra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41010 Sevilla, Spain
| | - Xavier Pintó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, 08908 Hospitalet de Llobregat, Spain;
| | - Josep A. Tur
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain
| | - José López-Miranda
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | - Naomi Cano-Ibáñez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Department of Preventive Medicine and Public Health, University of Granada, 18016 Granada, Spain
- Instituto de Investigación Biosanitaria, Complejo Hospitales Universitarios de Granada, Universidad de Granada, 18016 Granada, Spain
| | - Miguel Delgado-Rodríguez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Division of Preventive Medicine, Faculty of Medicine, University of Jaén, 23071 Jaen, Spain
| | - Pilar Matía-Martín
- Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain;
| | - Lidia Daimiel
- Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, 28029 Madrid, Spain;
| | - Vicente Martín Sánchez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Institute of Biomedicine (IBIOMED), University of León, 24071 Leon, Spain
| | - Josep Vidal
- CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
- Department of Endocrinology, Institut d’Investigacions Biomédiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Clotilde Vázquez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Endocrinology and Nutrition, Hospital Fundación Jimenez Díaz, Instituto de Investigaciones Biomédicas IISFJD, University Autonoma, 28040 Madrid, Spain
| | - Emili Ros
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain
| | - Francisco Javier Basterra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
| | - María Fernández de la Puente
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
| | - Eva M. Asensio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Olga Castañer
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Vanessa Bullón-Vela
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
| | - Lucas Tojal-Sierra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Enrique Gómez-Gracia
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, Instituto de Investigación Biomédica de Málaga-IBIMA, School of Medicine, University of Málaga, 29071 Malaga, Spain
| | | | - Jadwiga Konieczna
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
| | - Antonio García-Ríos
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | - Tamara Casañas-Quintana
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, 35016 Las Palmas de Gran Canaria, Spain
| | - María Rosa Bernal-Lopez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Regional University Hospital of Malaga, Instituto de Investigación Biomédica de Malaga (IBIMA), University of Malaga, 29010 Malaga, Spain
| | - José Manuel Santos-Lozano
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41010 Sevilla, Spain
| | - Virginia Esteve-Luque
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, 08908 Hospitalet de Llobregat, Spain;
| | - Cristina Bouzas
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain
| | - Zenaida Vázquez-Ruiz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
| | - Antoni Palau-Galindo
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- ABS Reus V. Centre d’Assistència Primària Marià Fortuny, SAGESSA, 43205 Reus, Spain
| | - Rocio Barragan
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Mercè López Grau
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Cristina Razquín
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
- Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
| | - Leire Goicolea-Güemez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Estefanía Toledo
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Manel Vila Vergaz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Rosa M. Lamuela-Raventós
- Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, 08921 Barcelona, Spain;
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
| | - Jordi Salas-Salvadó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
| |
Collapse
|
59
|
KOBYLIAK N, FALALYEYEVA T, KYRIACHENKO Y, TSEYSLYER Y, KOVALCHUK O, HADILIIA O, ESLAMI M, YOUSEFI B, ABENAVOLI L, FAGOONEE S, PELLICANO R. Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders. Minerva Endocrinol (Torino) 2022; 47:242-252. [DOI: 10.23736/s2724-6507.22.03752-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
60
|
Abstract
The increasing prevalence of metabolic diseases has become a severe public health problem. Gut microbiota play important roles in maintaining human health by modulating the host's metabolism. Recent evidences demonstrate that Akkermansia muciniphila is effective in improving metabolic disorders and is thus considered as a promising "next-generation beneficial microbe". In addition to the live A. muciniphila, similar or even stronger beneficial effects have been observed in pasteurized A. muciniphila and its components, including the outer membrane protein Amuc_1100, A. muciniphila-derived extracellular vesicles (AmEVs), and secreted protein P9. Hence, this paper presents a systemic review of recent progress in the effects and mechanisms of A. muciniphila and its components in the treatment of metabolic diseases, including obesity, type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic fatty liver disease, as well as perspectives on its future study.
Collapse
Affiliation(s)
- Juan Yan
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Lili Sheng
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China,Lili Sheng
| | - Houkai Li
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China,CONTACT Houkai Li Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai201203, China
| |
Collapse
|
61
|
Pérez-Monter C, Álvarez-Arce A, Nuño-Lambarri N, Escalona-Nández I, Juárez-Hernández E, Chávez-Tapia NC, Uribe M, Barbero-Becerra VJ. Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level. Int J Mol Sci 2022; 23:ijms23020991. [PMID: 35055177 PMCID: PMC8782000 DOI: 10.3390/ijms23020991] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 12/13/2021] [Accepted: 12/21/2021] [Indexed: 02/01/2023] Open
Abstract
Hepatic steatosis is characterized by triglyceride accumulation within hepatocytes in response to a high calorie intake, and it may be related to intestinal microbiota disturbances. The prebiotic inulin is a naturally occurring polysaccharide with a high dietary fiber content. Here, we evaluate the effect of inulin on the intestinal microbiota in a non-alcoholic fatty liver disease model. Mice exposed to a standard rodent diet or a fat-enriched diet, were supplemented or not, with inulin. Liver histology was evaluated with oil red O and H&E staining and the intestinal microbiota was determined in mice fecal samples by 16S rRNA sequencing. Inulin treatment effectively prevents liver steatosis in the fat-enriched diet group. We also observed that inulin re-shaped the intestinal microbiota at the phylum level, were Verrucomicrobia genus significantly increased in the fat-diet group; specifically, we observed that Akkermansia muciniphila increased by 5-fold with inulin supplementation. The family Prevotellaceae was also significantly increased in the fat-diet group. Overall, we propose that inulin supplementation in liver steatosis-affected animals, promotes a remodeling in the intestinal microbiota composition, which might regulate lipid metabolism, thus contributing to tackling liver steatosis.
Collapse
Affiliation(s)
- Carlos Pérez-Monter
- Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico;
- Correspondence: (C.P.-M.); (V.J.B.-B.)
| | - Alejandro Álvarez-Arce
- Departamento de Neuropatología Molecular, División de Neurociencias, Instituto de Fisiología Celular, UNAM, Mexico City 04510, Mexico;
| | - Natalia Nuño-Lambarri
- Unidad de Investigación Traslacional, Fundación Clínica Médica Sur, Mexico City 14050, Mexico; (N.N.-L.); (E.J.-H.); (N.C.C.-T.); (M.U.)
| | - Ivonne Escalona-Nández
- Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico;
| | - Eva Juárez-Hernández
- Unidad de Investigación Traslacional, Fundación Clínica Médica Sur, Mexico City 14050, Mexico; (N.N.-L.); (E.J.-H.); (N.C.C.-T.); (M.U.)
| | - Norberto C. Chávez-Tapia
- Unidad de Investigación Traslacional, Fundación Clínica Médica Sur, Mexico City 14050, Mexico; (N.N.-L.); (E.J.-H.); (N.C.C.-T.); (M.U.)
| | - Misael Uribe
- Unidad de Investigación Traslacional, Fundación Clínica Médica Sur, Mexico City 14050, Mexico; (N.N.-L.); (E.J.-H.); (N.C.C.-T.); (M.U.)
| | - Varenka J. Barbero-Becerra
- Unidad de Investigación Traslacional, Fundación Clínica Médica Sur, Mexico City 14050, Mexico; (N.N.-L.); (E.J.-H.); (N.C.C.-T.); (M.U.)
- Correspondence: (C.P.-M.); (V.J.B.-B.)
| |
Collapse
|
62
|
Unlike Glycerophosphocholine or Choline Chloride, Dietary Phosphatidylcholine Does Not Increase Plasma Trimethylamine- N-Oxide Levels in Sprague-Dawley Rats. Metabolites 2022; 12:metabo12010064. [PMID: 35050186 PMCID: PMC8779457 DOI: 10.3390/metabo12010064] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 01/07/2022] [Accepted: 01/07/2022] [Indexed: 02/04/2023] Open
Abstract
Choline, betaine, and L-carnitine are transformed into trimethylamine (TMA) by gut microbiota, absorbed into the liver, and oxidized into trimethylamine-N-oxide (TMAO) by flavin-containing monooxygenases. Elevated TMAO levels may negatively affect human health. As phosphatidylcholine (PC) is the main source of dietary choline, its intake or PC-rich foods may be harmful to human health; however, quantitative comparative information among dietary choline compounds (PC, glycerophosphocholine [GPC], and choline chloride [CC]) regarding in vivo generation of TMAO is lacking. Here, we compared the effects of PC, GPC, and CC on plasma TMAO levels in rats. Furthermore, we investigated their effects on gut microbiota at the genus level. Dietary PC did not affect plasma TMAO levels, whereas dietary GPC and CC significantly increased them. At the genus level, plasma TMAO levels were significantly negatively correlated with relative abundances of Anaerotruncus, Actinomyces, Enterococcus, Dialister, Clostridium XIVa, and Granulicatella; they were significantly positively correlated with that of Coprobacter. Moreover, the relative abundances of Anaerotruncus and Coprobacter were found to predict plasma TMAO levels. Therefore, dietary PC, unlike GPC or CC, does not increase plasma TMAO levels in rats. Furthermore, several gut microbes are associated with changes in plasma TMAO levels in rats fed with choline compounds.
Collapse
|
63
|
Aan FJ, Glibetic N, Montoya-Uribe V, Matter ML. COVID-19 and the Microbiome: The Gut-Lung Connection. COMPREHENSIVE GUT MICROBIOTA 2022. [PMCID: PMC8131000 DOI: 10.1016/b978-0-12-819265-8.00048-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
64
|
He Q, Dong H, Guo Y, Gong M, Xia Q, Lu F, Wang D. Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2022; 13:1074348. [PMID: 36465656 PMCID: PMC9715767 DOI: 10.3389/fendo.2022.1074348] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Accepted: 11/07/2022] [Indexed: 11/21/2022] Open
Abstract
Type 2 diabetes mellitus (T2DM) and its complications are major public health problems that seriously affect the quality of human life. The modification of intestinal microbiota has been widely recognized for the management of diabetes. The relationship between T2DM, intestinal microbiota, and active ingredient berberine (BBR) in intestinal microbiota was reviewed in this paper. First of all, the richness and functional changes of intestinal microbiota disrupt the intestinal environment through the destruction of the intestinal barrier and fermentation/degradation of pathogenic/protective metabolites, targeting the liver, pancreas, visceral adipose tissue (VAT), etc., to affect intestinal health, blood glucose, and lipids, insulin resistance and inflammation. Then, we focus on BBR, which protects the composition of intestinal microbiota, the changes of intestinal metabolites, and immune regulation disorder of the intestinal environment as the therapeutic mechanism as well as its current clinical trials. Further research can analyze the mechanism network of BBR to exert its therapeutic effect according to its multi-target compound action, to provide a theoretical basis for the use of different phytochemical components alone or in combination to prevent and treat T2DM or other metabolic diseases by regulating intestinal microbiota.
Collapse
Affiliation(s)
- Qiongyao He
- Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Hui Dong
- Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Yujin Guo
- Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Minmin Gong
- Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Qingsong Xia
- Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Fuer Lu
- Department of Integrated Traditional Chinese and Western Medicine, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China
- *Correspondence: Fuer Lu, ; Dingkun Wang,
| | - Dingkun Wang
- Department of Integrated Traditional Chinese and Western Medicine, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China
- *Correspondence: Fuer Lu, ; Dingkun Wang,
| |
Collapse
|
65
|
Acharya KD, Friedline RH, Ward DV, Graham ME, Tauer L, Zheng D, Hu X, de Vos WM, McCormick BA, Kim JK, Tetel MJ. Differential effects of Akkermansia-enriched fecal microbiota transplant on energy balance in female mice on high-fat diet. Front Endocrinol (Lausanne) 2022; 13:1010806. [PMID: 36387852 PMCID: PMC9647077 DOI: 10.3389/fendo.2022.1010806] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Accepted: 10/12/2022] [Indexed: 11/13/2022] Open
Abstract
Estrogens protect against weight gain and metabolic disruption in women and female rodents. Aberrations in the gut microbiota composition are linked to obesity and metabolic disorders. Furthermore, estrogen-mediated protection against diet-induced metabolic disruption is associated with modifications in gut microbiota. In this study, we tested if estradiol (E2)-mediated protection against obesity and metabolic disorders in female mice is dependent on gut microbiota. Specifically, we tested if fecal microbiota transplantation (FMT) from E2-treated lean female mice, supplemented with or without Akkermansia muciniphila, prevented high fat diet (HFD)-induced body weight gain, fat mass gain, and hyperglycemia in female recipients. FMT from, and cohousing with, E2-treated lean donors was not sufficient to transfer the metabolic benefits to the E2-deficient female recipients. Moreover, FMT from lean donors supplemented with A. muciniphila exacerbated HFD-induced hyperglycemia in E2-deficient recipients, suggesting its detrimental effect on the metabolic health of E2-deficient female rodents fed a HFD. Given that A. muciniphila attenuates HFD-induced metabolic insults in males, the present findings suggest a sex difference in the impact of this microbe on metabolic health.
Collapse
Affiliation(s)
- Kalpana D. Acharya
- Neuroscience Department, Wellesley College, Wellesley, MA, United States
| | | | - Doyle V. Ward
- Center for Microbiome Research, Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA, United States
- University of Massachusetts Chan Medical School, Worcester, MA, United States
| | - Madeline E. Graham
- Neuroscience Department, Wellesley College, Wellesley, MA, United States
| | - Lauren Tauer
- University of Massachusetts Chan Medical School, Worcester, MA, United States
| | - Doris Zheng
- University of Massachusetts Chan Medical School, Worcester, MA, United States
| | - Xiaodi Hu
- University of Massachusetts Chan Medical School, Worcester, MA, United States
| | - Willem M. de Vos
- Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands
- University of Helsinki, Helsinki, Finland
| | - Beth A. McCormick
- Center for Microbiome Research, Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA, United States
- University of Massachusetts Chan Medical School, Worcester, MA, United States
| | - Jason K. Kim
- University of Massachusetts Chan Medical School, Worcester, MA, United States
- Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States
| | - Marc J. Tetel
- Neuroscience Department, Wellesley College, Wellesley, MA, United States
- *Correspondence: Marc J. Tetel,
| |
Collapse
|
66
|
Beta-glucuronidase activity is associated with carbohydrate metabolism but not with androgen status in overweight and obese women with PCOS. Nutrition 2022; 97:111606. [DOI: 10.1016/j.nut.2022.111606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Revised: 11/24/2021] [Accepted: 01/16/2022] [Indexed: 11/21/2022]
|
67
|
Padilla-Martinez F, Wojciechowska G, Szczerbinski L, Kretowski A. Circulating Nucleic Acid-Based Biomarkers of Type 2 Diabetes. Int J Mol Sci 2021; 23:ijms23010295. [PMID: 35008723 PMCID: PMC8745431 DOI: 10.3390/ijms23010295] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Revised: 12/25/2021] [Accepted: 12/26/2021] [Indexed: 11/23/2022] Open
Abstract
Type 2 diabetes (T2D) is a deficiency in how the body regulates glucose. Uncontrolled T2D will result in chronic high blood sugar levels, eventually resulting in T2D complications. These complications, such as kidney, eye, and nerve damage, are even harder to treat. Identifying individuals at high risk of developing T2D and its complications is essential for early prevention and treatment. Numerous studies have been done to identify biomarkers for T2D diagnosis and prognosis. This review focuses on recent T2D biomarker studies based on circulating nucleic acids using different omics technologies: genomics, transcriptomics, and epigenomics. Omics studies have profiled biomarker candidates from blood, urine, and other non-invasive samples. Despite methodological differences, several candidate biomarkers were reported for the risk and diagnosis of T2D, the prognosis of T2D complications, and pharmacodynamics of T2D treatments. Future studies should be done to validate the findings in larger samples and blood-based biomarkers in non-invasive samples to support the realization of precision medicine for T2D.
Collapse
Affiliation(s)
- Felipe Padilla-Martinez
- Clinical Research Centre, Medical University of Bialystok, 15276 Białystok, Poland; (F.P.-M.); (L.S.); (A.K.)
| | - Gladys Wojciechowska
- Clinical Research Centre, Medical University of Bialystok, 15276 Białystok, Poland; (F.P.-M.); (L.S.); (A.K.)
- Correspondence:
| | - Lukasz Szczerbinski
- Clinical Research Centre, Medical University of Bialystok, 15276 Białystok, Poland; (F.P.-M.); (L.S.); (A.K.)
- Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15276 Białystok, Poland
| | - Adam Kretowski
- Clinical Research Centre, Medical University of Bialystok, 15276 Białystok, Poland; (F.P.-M.); (L.S.); (A.K.)
- Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15276 Białystok, Poland
| |
Collapse
|
68
|
Targeting the Gut Microbiome in Prader-Willi Syndrome. J Clin Med 2021; 10:jcm10225328. [PMID: 34830610 PMCID: PMC8625997 DOI: 10.3390/jcm10225328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 11/11/2021] [Accepted: 11/12/2021] [Indexed: 11/24/2022] Open
Abstract
Overwhelming evidence demonstrates an important role of the gut microbiome in the development of a wide range of diseases, including obesity, metabolic disorders, and mental health symptoms. Indeed, interventions targeting the gut microbiome are being actively investigated as a therapeutic strategy to tackle these diseases. Given that obesity and mental health symptoms are both hallmarks of Prader-Willi syndrome, targeting the gut microbiome may be a promising therapeutical strategy. Only a few studies have investigated the gut microbiome in the context of Prader-Willi syndrome and assessed the efficacy of probiotic supplementation as a therapeutic strategy for this disease. Here, we review the knowledge obtained to this date regarding the gut microbiome in individuals with Prader-Willi syndrome. The limited evidence available indicate that probiotic supplementation improves some metabolic and mental health aspects, however further studies are warranted to determine whether targeting the gut microbiome may constitute a safe and efficient strategy to treat individuals with Prader-Willi syndrome.
Collapse
|
69
|
Fecal Transplantation from db/db Mice Treated with Sodium Butyrate Attenuates Ischemic Stroke Injury. Microbiol Spectr 2021; 9:e0004221. [PMID: 34612696 PMCID: PMC8510264 DOI: 10.1128/spectrum.00042-21] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The complication of type 2 diabetes (T2D) exacerbates brain infarction in acute ischemic stroke (AIS). Because butyrate-producing bacteria are decreased in T2D and butyrate has been reported to be associated with attenuated brain injury in AIS, we hypothesize that administering butyrate could ameliorate T2D-associated exacerbation of brain infarction in AIS. Therefore, we first validated that Chinese AIS patients with T2D comorbidity have significantly lower levels of fecal butyrate-producing bacteria and butyrate than AIS patients without T2D. Then, we performed a 4-week intervention in T2D mice receiving either sodium butyrate (SB) or sodium chloride (NaCl) and found that SB improved the diabetic phenotype, altered the gut microbiota, and ameliorated brain injury after stroke. Fecal samples were collected from T2D mice after SB or NaCl treatment and were transplanted into antibiotic-treated C57BL/6 mice. After 2 weeks of transplantation, the gut microbiota profile and butyrate level of recipient mice were tested, and then the recipient mice were subjected to ischemic stroke. Stroke mice that received gut microbiota from SB-treated mice had a smaller cerebral infarct volume than mice that received gut microbiota from NaCl-treated mice. This protection was also associated with improvements in gut barrier function, reduced serum levels of lipopolysaccharide (LPS), LPS binding protein (LBP), and proinflammatory cytokines, and improvements in the blood-brain barrier. IMPORTANCE Ischemic stroke is a major global health burden, and T2D is a well-known comorbidity that aggravates brain injury after ischemic stroke. However, the underlying mechanism by which T2D exacerbates stroke injury has not been completely elucidated. A large amount of evidence suggests that the gut microbiota composition affects stroke outcomes. Our results showed that the gut microbiota of T2D aggravated brain injury after ischemic stroke and could be modified by SB to afford neuroprotection against stroke injury. These findings suggest that supplementation with SB is a potential therapeutic strategy for T2D patients with ischemic stroke.
Collapse
|
70
|
Qi L, Mao H, Lu X, Shi T, Wang J. Cinnamaldehyde Promotes the Intestinal Barrier Functions and Reshapes Gut Microbiome in Early Weaned Rats. Front Nutr 2021; 8:748503. [PMID: 34712688 PMCID: PMC8545821 DOI: 10.3389/fnut.2021.748503] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 09/16/2021] [Indexed: 01/04/2023] Open
Abstract
Cinnamaldehyde is an aromatic aldehyde isolated from the essential oil of cinnamon. It has been proved to possess various bioactivities such as anti-inflammation, anti-bacteria and antihypertensive. Nevertheless, early weaning could lead to intestinal stress, causing a range of intestinal health problems. The aim of this study is to explore the effects of cinnamaldehyde on gut barrier integrity, inflammatory responses, and intestinal microbiome of early weaned rats. In this study, treatment with cinnamaldehyde (100 or 200 mg/kg bodyweight/day) for 2 weeks significantly promoted the production of mucins in the colonic epithelial tissue of rats. Cinnamaldehyde supplementation significantly upregulated the expression of Muc2, TFF3 and the tight junction proteins (ZO-1, claudin-1, and occludin). Hematoxylin and eosin staining results showed that colonic histopathological changes were recovered by cinnamaldehyde supplementation. The mRNA expression of IL-6 and TNF-α were significantly decreased in the cinnamaldehyde groups while the TNF-α protein levels were significantly decreased in the two cinnamaldehyde groups. Cinnamaldehyde treatment obviously attenuated the activation of NF-κB signaling pathway in rat colonic tissue and suppressed the production of inflammatory cytokines. Furthermore, cinnamaldehyde supplementation remodeled the gut microbiome structure, at the genus level, Akkermansia, Bacteroides, Clostridium III, Psychrobacter, Intestinimonas were increased, whereas those of Ruminococcus, Escherichia/Shigella were obviously decreased in the cinnamaldehyde treated groups. These findings indicated that cinnamaldehyde could effectively enhance intestinal barrier integrity, ameliorate inflammatory responses and remodel gut microbiome in early weaned rats.
Collapse
Affiliation(s)
- Lili Qi
- School of Biological and Chemical Engineering, Ningbo Tech University, Ningbo, China
| | - Haiguang Mao
- School of Biological and Chemical Engineering, Ningbo Tech University, Ningbo, China
| | - Xiaohui Lu
- Ningbo Biomart Lifetech Co. Ltd, Ningbo, China
| | - Tingting Shi
- School of Biological and Chemical Engineering, Ningbo Tech University, Ningbo, China
| | - Jinbo Wang
- School of Biological and Chemical Engineering, Ningbo Tech University, Ningbo, China
| |
Collapse
|
71
|
Obesity and Pancreatic Cancer: Insight into Mechanisms. Cancers (Basel) 2021; 13:cancers13205067. [PMID: 34680216 PMCID: PMC8534007 DOI: 10.3390/cancers13205067] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 10/06/2021] [Accepted: 10/08/2021] [Indexed: 12/12/2022] Open
Abstract
Simple Summary Obesity is recognized as a chronic progressive disease and risk factor for many human diseases. The high and increasing number of obese people may underlie the expected increase in pancreatic cancer cases in the United States. There are several pathways discussed that link obesity with pancreatic cancer. Adipose tissue and adipose tissue-released factors may thereby play an important role. This review discusses selected mechanisms that may accelerate pancreatic cancer development in obesity. Abstract The prevalence of obesity in adults and children has dramatically increased over the past decades. Obesity has been declared a chronic progressive disease and is a risk factor for a number of metabolic, inflammatory, and neoplastic diseases. There is clear epidemiologic and preclinical evidence that obesity is a risk factor for pancreatic cancer. Among various potential mechanisms linking obesity with pancreatic cancer, the adipose tissue and obesity-associated adipose tissue inflammation play a central role. The current review discusses selected topics and mechanisms that attracted recent interest and that may underlie the promoting effects of obesity in pancreatic cancer. These topics include the impact of obesity on KRAS activity, the role of visceral adipose tissue, intrapancreatic fat, adipose tissue inflammation, and adipokines on pancreatic cancer development. Current research on lipocalin-2, fibroblast growth factor 21, and Wnt5a is discussed. Furthermore, the significance of obesity-associated insulin resistance with hyperinsulinemia and obesity-induced gut dysbiosis with metabolic endotoxemia is reviewed. Given the central role that is occupied by the adipose tissue in obesity-promoted pancreatic cancer development, preventive and interceptive strategies should be aimed at attenuating obesity-associated adipose tissue inflammation and/or at targeting specific molecules that mechanistically link adipose tissue with pancreatic cancer in obese patients.
Collapse
|
72
|
Yu K, Yu CG, Yin XQ, Wang ZW, Wang XB, Wang LL, Guo S, An YX, Zhao D. Metabolites of gut microbiome are associated with glucose metabolism in non-diabetic obese adults: a Chinese monozygotic twin study. Diabetol Metab Syndr 2021; 13:106. [PMID: 34627359 PMCID: PMC8501618 DOI: 10.1186/s13098-021-00724-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2021] [Accepted: 09/17/2021] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Evidence suggests gut microbiome is associated with diabetes. However, it's unclear whether the association remains in non-diabetic participants. A Chinese monozygotic twin study, in which the participants are without diabetes, and are not taking any medications, was conducted to explore the potential association. METHODS Nine pairs of adult monozygotic twins were enrolled and divided into two twin-pair groups (a and b). Clinical and laboratory measurements were conducted. Visceral adipose tissue (VAT) was assessed. Fecal samples were collected to analyze the microbiome composition by 16S rDNA gene amplicon sequencing. Liquid chromatography mass spectrometry was performed to detect the metabolites. RESULTS The participants aged 53 years old averagely, with 8 (88.9%) pairs were women. All the participants were obese with VAT higher than 100 cm2 (152.2 ± 31.6). There was no significant difference of VAT between the twin groups (153.6 ± 30.4 cm2 vs. 150.8 ± 29.5 cm2, p = 0.54). Other clinical measurements, including BMI, lipid profiles, fasting insulin and blood glucose, were also not significantly different between groups (p ≥ 0.056), whereas HbA1c level of group a is significantly higher than group b (5.8 ± 0.3% vs. 5.6 ± 0.2%, p = 0.008). The number and richness of OTUs are relatively higher in group a, and 13 metabolites were significantly different between two groups. Furthermore, several of the 13 metabolites could be significantly linked to special taxons. The potential pathway involved drug metabolism-other enzymes, Tryptophan metabolism and Citrate cycle. CONCLUSIONS Gut microbiome composition and their metabolites may modulate glucose metabolism in obese adults without diabetes, through Tryptophan metabolism, Citrate cycle and other pathways.
Collapse
Affiliation(s)
- Ke Yu
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China
| | - Cai-Guo Yu
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China
| | - Xing-Qi Yin
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China
| | - Zong-Wei Wang
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China
| | - Xiao-Bo Wang
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China
| | - Li-Li Wang
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China
| | - Shuang Guo
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China
| | - Ya-Xin An
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China
| | - Dong Zhao
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.
- Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, China.
| |
Collapse
|
73
|
β-Glucan Extracted from Highland Barley Alleviates Dextran Sulfate Sodium-Induced Ulcerative Colitis in C57BL/6J Mice. Molecules 2021; 26:molecules26195812. [PMID: 34641356 PMCID: PMC8510048 DOI: 10.3390/molecules26195812] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 09/20/2021] [Accepted: 09/20/2021] [Indexed: 12/26/2022] Open
Abstract
Inflammatory bowel disease (IBD), which significantly affects human health, has two primary presentations: Crohn’s disease and ulcerative colitis (UC). Highland barley is the most common food crop for Tibetans and contains much more β-glucan than any other crop. Highland barley β-glucan (HBBG) can relieve the gastrointestinal dysfunction and promote intestines health. This study aimed to evaluate whether HBBG can relieve UC in mice. A mouse model of UC was established by adding 2% dextran sulfate sodium (DSS) to drinking water for 1 week. UC was alleviated after the introduction of the HBBG diet, as indicated by reductions in the disease activity index (DAI) score, histopathological damage, and the concentration of colonic myeloperoxidase (MPO), along with an improvement in colonic atrophy. Furthermore, we found that HBBG can increase the relative transcriptional levels of genes encoding ZO-1, claudin-1, occludin, and mucin2 (MUC2), thereby reducing intestinal permeability. Additionally, HBBG maintained the balance of proinflammatory and anti-inflammatory cytokines and modulated the structure of the intestinal flora.
Collapse
|
74
|
Bonsembiante L, Targher G, Maffeis C. Type 2 Diabetes and Dietary Carbohydrate Intake of Adolescents and Young Adults: What Is the Impact of Different Choices? Nutrients 2021; 13:3344. [PMID: 34684345 PMCID: PMC8537173 DOI: 10.3390/nu13103344] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 09/20/2021] [Accepted: 09/21/2021] [Indexed: 12/05/2022] Open
Abstract
Type 2 diabetes mellitus has a high prevalence worldwide, with a rapidly increasing incidence even in youth. Nutrition, dietary macronutrient composition, and in particular dietary carbohydrates play a major role in the development of type 2 diabetes. The aim of this narrative review is to discuss the current evidence on the role of dietary carbohydrates in the prevention and management of type 2 diabetes. The digestibility or availability of carbohydrates and their glycemic index (and glycemic load) markedly influence the glycemic response. High consumption of dietary fiber is beneficial for management of type 2 diabetes, whereas high consumption of both glycemic starch and sugars may have a harmful effect on glucose metabolism, thereby increasing the risk of developing type 2 diabetes in the presence of genetic predisposition or making its glycemic control more difficult to achieve in people with established T2D. Therefore, the same dietary macronutrient may have harmful or beneficial effects on type 2 diabetes mainly depending on the subtypes consumed. Some other factors are involved in glucose metabolism, such as meal composition, gut microbiota and genetics. For this reason, the glycemic response after carbohydrate consumption is not easy to predict in the single individual. Nutrition suggested to subjects with known type 2 diabetes should be always person-centered, considering the individual features of each subject.
Collapse
Affiliation(s)
- Luisa Bonsembiante
- Section of Pediatric Diabetes and Metabolic Disorders Unit, Department of Surgical Sciences, Dentistry, Paediatrics and Gynaecology, Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. Stefani, 1, 37126 Verona, Italy;
| | - Giovanni Targher
- Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. Stefani, 1, 37126 Verona, Italy;
| | - Claudio Maffeis
- Section of Pediatric Diabetes and Metabolic Disorders Unit, Department of Surgical Sciences, Dentistry, Paediatrics and Gynaecology, Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. Stefani, 1, 37126 Verona, Italy;
| |
Collapse
|
75
|
Tudela H, Claus SP, Saleh M. Next Generation Microbiome Research: Identification of Keystone Species in the Metabolic Regulation of Host-Gut Microbiota Interplay. Front Cell Dev Biol 2021; 9:719072. [PMID: 34540837 PMCID: PMC8440917 DOI: 10.3389/fcell.2021.719072] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Accepted: 08/02/2021] [Indexed: 12/12/2022] Open
Abstract
The community of the diverse microorganisms residing in the gastrointestinal tract, known as the gut microbiota, is exceedingly being studied for its impact on health and disease. This community plays a major role in nutrient metabolism, maintenance of the intestinal epithelial barrier but also in local and systemic immunomodulation. A dysbiosis of the gut microbiota, characterized by an unbalanced microbial ecology, often leads to a loss of essential functions that may be associated with proinflammatory conditions. Specifically, some key microbes that are depleted in dysbiotic ecosystems, called keystone species, carry unique functions that are essential for the balance of the microbiota. In this review, we discuss current understanding of reported keystone species and their proposed functions in health. We also elaborate on current and future bioinformatics tools needed to identify missing functions in the gut carried by keystone species. We propose that the identification of such keystone species functions is a major step for the understanding of microbiome dynamics in disease and toward the development of microbiome-based therapeutics.
Collapse
Affiliation(s)
- Héloïse Tudela
- YSOPIA Bioscience, Bordeaux, France
- ImmunoConcEpT, CNRS UMR 5164, University of Bordeaux, Bordeaux, France
| | | | - Maya Saleh
- ImmunoConcEpT, CNRS UMR 5164, University of Bordeaux, Bordeaux, France
- Department of Medicine, McGill University, Montreal, QC, Canada
| |
Collapse
|
76
|
Baik HU, Seo BK, Kim GR, Ku JE. A Keyword Analysis Study on Postpartum Obesity Using Big Data. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:ijerph18168807. [PMID: 34444551 PMCID: PMC8394976 DOI: 10.3390/ijerph18168807] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 08/12/2021] [Accepted: 08/17/2021] [Indexed: 11/16/2022]
Abstract
This study selected Google and Naver, the most recognizable Internet portals in Korea, as subjects for analysis. “Postpartum obesity” and “postpartum depression” were used as keywords for data collection. This study aimed to provide basic data for solving maternal problems using big data. Keywords related to postpartum obesity were collected from the portal site Google from 1 January 2019 to 31 December 2019. The collected data were analyzed through simple frequency analysis, N-gram analysis, and keyword network. This study can be used as basic data for postpartum obesity-related programs or academic research. It is also expected to be used for research on the development of a mobile-based customized healthcare system focused on maternal health. Previous papers and data are still insufficient at solving the physical and mental problems related to postpartum obesity and depression. It is necessary to find ways to continuously integrate and collect data from mothers across the country.
Collapse
Affiliation(s)
- Hyung-ui Baik
- Department of Addiction Rehabilitation and Social Welfare, Eulji University, 553 Sanseong-daero, Sujeong-gu, Seongnam-si 13135, Gyeonggi-do, Korea; (H.-u.B.); (B.-K.S.)
| | - Bo-Kyung Seo
- Department of Addiction Rehabilitation and Social Welfare, Eulji University, 553 Sanseong-daero, Sujeong-gu, Seongnam-si 13135, Gyeonggi-do, Korea; (H.-u.B.); (B.-K.S.)
| | - Gyu-Ri Kim
- Department of Beauty and Cosmetic Science, Eulji University, 553 Sanseong-daero, Sujeong-gu, Seongnam-si 13135, Gyeonggi-do, Korea
- Correspondence: ; Tel.: +82-010-5009-5465
| | - Jung-Eun Ku
- Department of Beauty Care, Bucheon University, 25 Sinheung-ro 56 Beon-gil, Wonmi-gu, Bucheon-si 14632, Gyeonggi-do, Korea;
| |
Collapse
|
77
|
Wang S, Zhang L, Wang D, Huang M, Zhao J, Malik V, Liu X, Sun L, Lin X, Chen Y. Gut Microbiota Composition is Associated with Responses to Peanut Intervention in Multiple Parameters Among Adults with Metabolic Syndrome Risk. Mol Nutr Food Res 2021; 65:e2001051. [PMID: 34327851 DOI: 10.1002/mnfr.202001051] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 07/18/2021] [Indexed: 11/10/2022]
Abstract
INTRODUCTION Peanuts are widely consumed as a meal ingredient and a snack, and are commonly considered as a healthy food based on their nutrient profile. Peanut consumption has been associated with a lower risk of metabolic syndrome (MetS) in epidemiological studies. This study aims to investigate whether consuming peanuts affects the gut microbiota in adults with risk of MetS and whether the intervention effect of peanuts is associated with gut microbiota composition. METHODS AND RESULTS This study analyzes the gut microbiota of subjects from a 12-week randomized clinical trial comparing consumption of either peanuts or isocaloric carbohydrate bars. It is observed that there is high inter-individual variability on multiple clinical and anthropometrical parameters in response to peanut consumption. Meanwhile, the gut microbiota composition is also highly person-specific and have minor changes when compared laterally or longitudinally. This study employs a machine-learning algorithm and establishes prediction models using the microbiome data and the responsiveness data of different parameters in subjects with peanut intervention. As a result, it is found that the improvement of MetS risk and numerous parameters, including diastolic blood pressure, body weight, waist circumference, and fasting blood glucose level can be predicted for responsiveness with high accuracy that has a value of area under curve over 0.70 by receiver operating characteristic analysis. CONCLUSION Together, the findings of this study suggest that individual gut microbiota configuration may modulate host metabolism and alter an individual's response to peanut intervention, thus highlighting the importance of personalized nutrition.
Collapse
Affiliation(s)
- Shuo Wang
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China
| | - Lingling Zhang
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China
| | - Di Wang
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China
| | - Meiqin Huang
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China
| | - Jingyu Zhao
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China
| | - Vasanti Malik
- Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, 02115, USA.,Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - Xiaoran Liu
- Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, 02115, USA.,Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA
| | - Liang Sun
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China
| | - Xu Lin
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China
| | - Yan Chen
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China
| |
Collapse
|
78
|
Acharya KD, Noh HL, Graham ME, Suk S, Friedline RH, Gomez CC, Parakoyi AER, Chen J, Kim JK, Tetel MJ. Distinct Changes in Gut Microbiota Are Associated with Estradiol-Mediated Protection from Diet-Induced Obesity in Female Mice. Metabolites 2021; 11:metabo11080499. [PMID: 34436440 PMCID: PMC8398128 DOI: 10.3390/metabo11080499] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 07/24/2021] [Accepted: 07/27/2021] [Indexed: 01/14/2023] Open
Abstract
A decrease in ovarian estrogens in postmenopausal women increases the risk of weight gain, cardiovascular disease, type 2 diabetes, and chronic inflammation. While it is known that gut microbiota regulates energy homeostasis, it is unclear if gut microbiota is associated with estradiol regulation of metabolism. In this study, we tested if estradiol-mediated protection from high-fat diet (HFD)-induced obesity and metabolic changes are associated with longitudinal alterations in gut microbiota in female mice. Ovariectomized adult mice with vehicle or estradiol (E2) implants were fed chow for two weeks and HFD for four weeks. As reported previously, E2 increased energy expenditure, physical activity, insulin sensitivity, and whole-body glucose turnover. Interestingly, E2 decreased the tight junction protein occludin, suggesting E2 affects gut epithelial integrity. Moreover, E2 increased Akkermansia and decreased Erysipleotrichaceae and Streptococcaceae. Furthermore, Coprobacillus and Lactococcus were positively correlated, while Akkermansia was negatively correlated, with body weight and fat mass. These results suggest that changes in gut epithelial barrier and specific gut microbiota contribute to E2-mediated protection against diet-induced obesity and metabolic dysregulation. These findings provide support for the gut microbiota as a therapeutic target for treating estrogen-dependent metabolic disorders in women.
Collapse
Affiliation(s)
- Kalpana D. Acharya
- Neuroscience Department, Wellesley College, Wellesley, MA 02481, USA; (K.D.A.); (M.E.G.); (C.C.G.); (A.E.R.P.)
| | - Hye L. Noh
- Program in Molecular Medicine, Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; (H.L.N.); (S.S.); (R.H.F.); (J.K.K.)
| | - Madeline E. Graham
- Neuroscience Department, Wellesley College, Wellesley, MA 02481, USA; (K.D.A.); (M.E.G.); (C.C.G.); (A.E.R.P.)
| | - Sujin Suk
- Program in Molecular Medicine, Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; (H.L.N.); (S.S.); (R.H.F.); (J.K.K.)
| | - Randall H. Friedline
- Program in Molecular Medicine, Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; (H.L.N.); (S.S.); (R.H.F.); (J.K.K.)
| | - Cesiah C. Gomez
- Neuroscience Department, Wellesley College, Wellesley, MA 02481, USA; (K.D.A.); (M.E.G.); (C.C.G.); (A.E.R.P.)
| | - Abigail E. R. Parakoyi
- Neuroscience Department, Wellesley College, Wellesley, MA 02481, USA; (K.D.A.); (M.E.G.); (C.C.G.); (A.E.R.P.)
| | - Jun Chen
- Department of Health Sciences Research & Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA;
| | - Jason K. Kim
- Program in Molecular Medicine, Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; (H.L.N.); (S.S.); (R.H.F.); (J.K.K.)
| | - Marc J. Tetel
- Neuroscience Department, Wellesley College, Wellesley, MA 02481, USA; (K.D.A.); (M.E.G.); (C.C.G.); (A.E.R.P.)
- Correspondence:
| |
Collapse
|
79
|
Arif M, Zhang C, Li X, Güngör C, Çakmak B, Arslantürk M, Tebani A, Özcan B, Subaş O, Zhou W, Piening B, Turkez H, Fagerberg L, Price N, Hood L, Snyder M, Nielsen J, Uhlen M, Mardinoglu A. iNetModels 2.0: an interactive visualization and database of multi-omics data. Nucleic Acids Res 2021; 49:W271-W276. [PMID: 33849075 DOI: 10.1101/2021.11.10.468051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 03/10/2021] [Accepted: 03/29/2021] [Indexed: 05/20/2023] Open
Abstract
It is essential to reveal the associations between various omics data for a comprehensive understanding of the altered biological process in human wellness and disease. To date, very few studies have focused on collecting and exhibiting multi-omics associations in a single database. Here, we present iNetModels, an interactive database and visualization platform of Multi-Omics Biological Networks (MOBNs). This platform describes the associations between the clinical chemistry, anthropometric parameters, plasma proteomics, plasma metabolomics, as well as metagenomics for oral and gut microbiome obtained from the same individuals. Moreover, iNetModels includes tissue- and cancer-specific Gene Co-expression Networks (GCNs) for exploring the connections between the specific genes. This platform allows the user to interactively explore a single feature's association with other omics data and customize its particular context (e.g. male/female specific). The users can also register their data for sharing and visualization of the MOBNs and GCNs. Moreover, iNetModels allows users who do not have a bioinformatics background to facilitate human wellness and disease research. iNetModels can be accessed freely at https://inetmodels.com without any limitation.
Collapse
Affiliation(s)
- Muhammad Arif
- Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-171 21, Sweden
| | - Cheng Zhang
- Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-171 21, Sweden
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou, Henan Province, PR 450001, China
| | - Xiangyu Li
- Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-171 21, Sweden
| | - Cem Güngör
- Bash Biotech Inc, 600 West Broadway, Suite 700, San Diego, CA, USA
| | - Buğra Çakmak
- Bash Biotech Inc, 600 West Broadway, Suite 700, San Diego, CA, USA
| | - Metin Arslantürk
- Bash Biotech Inc, 600 West Broadway, Suite 700, San Diego, CA, USA
| | - Abdellah Tebani
- Department of Metabolic Biochemistry, Rouen University Hospital, 76000 Rouen, France
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France
| | - Berkay Özcan
- Bash Biotech Inc, 600 West Broadway, Suite 700, San Diego, CA, USA
| | - Oğuzhan Subaş
- Bash Biotech Inc, 600 West Broadway, Suite 700, San Diego, CA, USA
| | - Wenyu Zhou
- Department of Genetics, Stanford University, Stanford, CA 94305, USA
| | - Brian Piening
- Providence Cancer Center, Oregon Area, Portland, OR, USA
| | - Hasan Turkez
- Department of Medical Biology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
| | - Linn Fagerberg
- Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-171 21, Sweden
| | | | - Leroy Hood
- Institute of Systems Biology, Seattle, USA
| | - Michael Snyder
- Department of Genetics, Stanford University, Stanford, CA 94305, USA
| | - Jens Nielsen
- Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
| | - Mathias Uhlen
- Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-171 21, Sweden
| | - Adil Mardinoglu
- Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-171 21, Sweden
- Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London SE1 9RT, UK
| |
Collapse
|
80
|
Meier MJ, Nguyen KC, Crosthwait J, Kawata A, Rigden M, Leingartner K, Wong A, Holloway A, Shwed PS, Beaudette L, Navarro M, Wade M, Tayabali AF. Low dose antibiotic ingestion potentiates systemic and microbiome changes induced by silver nanoparticles. NANOIMPACT 2021; 23:100343. [PMID: 35559844 DOI: 10.1016/j.impact.2021.100343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 06/29/2021] [Accepted: 07/12/2021] [Indexed: 06/15/2023]
Abstract
Changes in the mammalian gut microbiome are linked to the impairment of immunological function and numerous other pathologies. Antimicrobial silver nanoparticles (AgNPs) are incorporated into numerous consumer products (e.g., clothing, cosmetics, food packaging), which may directly impact the gut microbiome through ingestion. The human health impact of chronic AgNP ingestion is still uncertain, but evidence from exposure to other antimicrobials provides a strong rationale to assess AgNP effects on organ function, immunity, metabolism, and gut-associated microbiota. To investigate this, mice were gavaged daily for 5 weeks with saline, AgNPs, antibiotics (ciprofloxacin and metronidazole), or AgNPs combined with antibiotics. Animals were weighed daily, assessed for glucose tolerance, organ function, tissue and blood cytokine and leukocyte levels. At the end of the study, we used 16S rDNA amplicon and whole-metagenome shotgun sequencing to assess changes in the gut microbiome. In mice exposed to both AgNPs and antibiotics, silver was found in the stomach, and small and large intestines, but negligible amounts were present in other organs examined. Mice exposed to AgNPs alone showed minimal tissue silver levels. Antibiotics, but not AgNPs, altered glucose metabolism. Mice given AgNPs and antibiotics together demonstrated slower weight gain, reduced peripheral lymphocytes, and elevated splenic, but not circulatory markers of inflammation. 16S rDNA profiling of cecum and feces and metagenomic sequencing of fecal DNA demonstrated that combined AgNP-antibiotic treatment also significantly altered the structure and function of the gut microbiota, including depletion of the indicator species Akkermansia muciniphila. This study provides evidence for possible biological effects from repeated ingestion of AgNP-containing consumer products when antibiotics are also being used and raises concern that an impaired gut microbiome (e.g., through antibiotic use) can potentiate the harm from chemical exposures such as AgNPs.
Collapse
Affiliation(s)
- Matthew J Meier
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada
| | - K C Nguyen
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada; New Substances Assessment and Control Bureau, Health Canada, Ottawa, Canada
| | - J Crosthwait
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada
| | - A Kawata
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada
| | - M Rigden
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada
| | - K Leingartner
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada
| | - A Wong
- Department of Biology, Carleton University, Ottawa, Canada
| | - A Holloway
- Department of Obstetrics and Gynecology, McMaster University, Hamilton, Canada
| | - P S Shwed
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada
| | - Lee Beaudette
- Ecotoxicology and Wildlife Health Division, Environment and Climate Change Canada, Ottawa, Canada
| | - M Navarro
- Bureau of Chemical Safety, Health Canada, Ottawa, Canada
| | - M Wade
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada
| | - A F Tayabali
- Environmental Health, Science and Research Bureau, Health Canada, Ottawa, Canada.
| |
Collapse
|
81
|
Becken B, Davey L, Middleton DR, Mueller KD, Sharma A, Holmes ZC, Dallow E, Remick B, Barton GM, David LA, McCann JR, Armstrong SC, Malkus P, Valdivia RH. Genotypic and Phenotypic Diversity among Human Isolates of Akkermansia muciniphila. mBio 2021; 12:e00478-21. [PMID: 34006653 PMCID: PMC8262928 DOI: 10.1128/mbio.00478-21] [Citation(s) in RCA: 55] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 04/05/2021] [Indexed: 12/12/2022] Open
Abstract
The mucophilic anaerobic bacterium Akkermansia muciniphila is a prominent member of the gastrointestinal (GI) microbiota and the only known species of the Verrucomicrobia phylum in the mammalian gut. A high prevalence of A. muciniphila in adult humans is associated with leanness and a lower risk for the development of obesity and diabetes. Four distinct A. muciniphila phylogenetic groups have been described, but little is known about their relative abundance in humans or how they impact human metabolic health. In this study, we isolated and characterized 71 new A. muciniphila strains from a cohort of children and adolescents undergoing treatment for obesity. Based on genomic and phenotypic analysis of these strains, we found several phylogroup-specific phenotypes that may impact the colonization of the GI tract or modulate host functions, such as oxygen tolerance, adherence to epithelial cells, iron and sulfur metabolism, and bacterial aggregation. In antibiotic-treated mice, phylogroups AmIV and AmII outcompeted AmI strains. In children and adolescents, AmI strains were most prominent, but we observed high variance in A. muciniphila abundance and single phylogroup dominance, with phylogroup switching occurring in a small subset of patients. Overall, these results highlight that the ecological principles determining which A. muciniphila phylogroup predominates in humans are complex and that A. muciniphila strain genetic and phenotypic diversity may represent an important variable that should be taken into account when making inferences as to this microbe's impact on its host's health.IMPORTANCE The abundance of Akkermansia muciniphila in the gastrointestinal (GI) tract is linked to multiple positive health outcomes. There are four known A. muciniphila phylogroups, yet the prevalence of these phylogroups and how they vary in their ability to influence human health is largely unknown. In this study, we performed a genomic and phenotypic analysis of 71 A. muciniphila strains and identified phylogroup-specific traits such as oxygen tolerance, adherence, and sulfur acquisition that likely influence colonization of the GI tract and differentially impact metabolic and immunological health. In humans, we observed that single Akkermansia phylogroups predominate at a given time but that the phylotype can switch in an individual. This collection of strains provides the foundation for the functional characterization of A. muciniphila phylogroup-specific effects on the multitude of host outcomes associated with Akkermansia colonization, including protection from obesity, diabetes, colitis, and neurological diseases, as well as enhanced responses to cancer immunotherapies.
Collapse
Affiliation(s)
- Bradford Becken
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
- Department of Pediatrics, Duke University Hospital, Durham, North Carolina, USA
| | - Lauren Davey
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Dustin R Middleton
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Katherine D Mueller
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Agastya Sharma
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Zachary C Holmes
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Eric Dallow
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Brenna Remick
- Division of Immunology & Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, California, USA
| | - Gregory M Barton
- Division of Immunology & Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, California, USA
| | - Lawrence A David
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Jessica R McCann
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Sarah C Armstrong
- Department of Pediatrics, Duke University Hospital, Durham, North Carolina, USA
| | - Per Malkus
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| | - Raphael H Valdivia
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
| |
Collapse
|
82
|
Shi T, Bian X, Yao Z, Wang Y, Gao W, Guo C. Quercetin improves gut dysbiosis in antibiotic-treated mice. Food Funct 2021; 11:8003-8013. [PMID: 32845255 DOI: 10.1039/d0fo01439g] [Citation(s) in RCA: 66] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The diversity and activity of the gut microbiota residing in humans and animals are significantly influenced by the diet. Quercetin, one of the representative polyphenols in human diets, possesses a wide range of biological properties. The aim of this study was to investigate the prebiotic effects of quercetin in antibiotic-treated mice. Gut dysbiosis was successfully induced in mice by treatment with an antibiotic cocktail. Gas chromatography and 16S rDNA high-throughput sequencing techniques were used to investigate short-chain fatty acid content and gut microbial diversity and composition. The results showed that quercetin supplementation significantly improved the diversity of the gut bacterial community in antibiotic-treated mice (P < 0.05). Meanwhile, intestinal barrier function was also recovered remarkably as indicated by a decrease in the content of serum d-lactic acid and the activity of serum diamine oxidase (P < 0.05). The length of intestinal villi and mucosal thickness were also significantly increased in response to quercetin treatment (P < 0.05). Furthermore, the production of butyrate in faeces was enhanced significantly in quercetin-treated mice (P < 0.05). In conclusion, quercetin is effective in recovering gut microbiota in mice after antibiotic treatment and may act as a prebiotic in combatting gut dysbiosis.
Collapse
Affiliation(s)
- Tala Shi
- Institute of Environmental and Operational Medicine, Tianjin, China. and Department of Nutrition and Food Hygiene, Binzhou Medical University, Yantai, China
| | - Xiangyu Bian
- Institute of Environmental and Operational Medicine, Tianjin, China.
| | - Zhanxin Yao
- Institute of Environmental and Operational Medicine, Tianjin, China.
| | - Yawen Wang
- Institute of Environmental and Operational Medicine, Tianjin, China.
| | - Weina Gao
- Institute of Environmental and Operational Medicine, Tianjin, China.
| | - Changjiang Guo
- Institute of Environmental and Operational Medicine, Tianjin, China.
| |
Collapse
|
83
|
Newman TM, Shively CA, Register TC, Appt SE, Yadav H, Colwell RR, Fanelli B, Dadlani M, Graubics K, Nguyen UT, Ramamoorthy S, Uberseder B, Clear KYJ, Wilson AS, Reeves KD, Chappell MC, Tooze JA, Cook KL. Diet, obesity, and the gut microbiome as determinants modulating metabolic outcomes in a non-human primate model. MICROBIOME 2021; 9:100. [PMID: 33952353 PMCID: PMC8101030 DOI: 10.1186/s40168-021-01069-y] [Citation(s) in RCA: 49] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 04/01/2021] [Indexed: 05/17/2023]
Abstract
BACKGROUND The objective of this study was to increase understanding of the complex interactions between diet, obesity, and the gut microbiome of adult female non-human primates (NHPs). Subjects consumed either a Western (n=15) or Mediterranean (n=14) diet designed to represent human dietary patterns for 31 months. Body composition was determined using CT, fecal samples were collected, and shotgun metagenomic sequencing was performed. Gut microbiome results were grouped by diet and adiposity. RESULTS Diet was the main contributor to gut microbiome bacterial diversity. Adiposity within each diet was associated with subtle shifts in the proportional abundance of several taxa. Mediterranean diet-fed NHPs with lower body fat had a greater proportion of Lactobacillus animalis than their higher body fat counterparts. Higher body fat Western diet-fed NHPs had more Ruminococcus champaneliensis and less Bacteroides uniformis than their low body fat counterparts. Western diet-fed NHPs had significantly higher levels of Prevotella copri than Mediterranean diet NHPs. Western diet-fed subjects were stratified by P. copri abundance (P. copriHIGH versus P. copriLOW), which was not associated with adiposity. Overall, Western diet-fed animals in the P. copriHIGH group showed greater proportional abundance of B. ovatus, B. faecis, P. stercorea, P. brevis, and Faecalibacterium prausnitzii than those in the Western P. copriLOW group. Western diet P. copriLOW subjects had a greater proportion of Eubacterium siraeum. E. siraeum negatively correlated with P. copri proportional abundance regardless of dietary consumption. In the Western diet group, Shannon diversity was significantly higher in P. copriLOW when compared to P. copriHIGH subjects. Furthermore, gut E. siraeum abundance positively correlated with HDL plasma cholesterol indicating that those in the P. copriLOW population may represent a more metabolically healthy population. Untargeted metabolomics on urine and plasma from Western diet-fed P. copriHIGH and P. copriLOW subjects suggest early kidney dysfunction in Western diet-fed P. copriHIGH subjects. CONCLUSIONS In summary, the data indicate diet to be the major influencer of gut bacterial diversity. However, diet and adiposity must be considered together when analyzing changes in abundance of specific bacterial taxa. Interestingly, P. copri appears to mediate metabolic dysfunction in Western diet-fed NHPs. Video abstract.
Collapse
Affiliation(s)
- Tiffany M Newman
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Carol A Shively
- Department of Pathology, Section of Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Thomas C Register
- Department of Pathology, Section of Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Susan E Appt
- Department of Pathology, Section of Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Hariom Yadav
- Department of Neurosurgery and Brain Repair, USF Center for Microbiome Research University of South Florida Morsani College of Medicine, Tampa, FL, USA
- Department of Internal Medicine-Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | | | | | | | | | | | | | - Beth Uberseder
- Department of Pathology, Section of Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Kenysha Y J Clear
- Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Adam S Wilson
- Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Kimberly D Reeves
- Department of Internal Medicine-Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Mark C Chappell
- Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Janet A Tooze
- Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
- Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Katherine L Cook
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
- Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
- Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
- Wake Forest School of Medicine, 575 N. Patterson Ave, Suite 340, Winston-Salem, NC, 27101, USA.
| |
Collapse
|
84
|
Croci S, D’Apolito LI, Gasperi V, Catani MV, Savini I. Dietary Strategies for Management of Metabolic Syndrome: Role of Gut Microbiota Metabolites. Nutrients 2021; 13:nu13051389. [PMID: 33919016 PMCID: PMC8142993 DOI: 10.3390/nu13051389] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Revised: 04/15/2021] [Accepted: 04/16/2021] [Indexed: 12/21/2022] Open
Abstract
Metabolic syndrome (MetS) is a complex pathophysiological state with incidence similar to that of a global epidemic and represents a risk factor for the onset of chronic non-communicable degenerative diseases (NCDDs), including cardiovascular disease (CVD), type 2 diabetes mellitus, chronic kidney disease, and some types of cancer. A plethora of literature data suggest the potential role of gut microbiota in interfering with the host metabolism, thus influencing several MetS risk factors. Perturbation of the gut microbiota’s composition and activity, a condition known as dysbiosis, is involved in the etiopathogenesis of multiple chronic diseases. Recent studies have shown that some micro-organism-derived metabolites (including trimethylamine N-oxide (TMAO), lipopolysaccharide (LPS) of Gram-negative bacteria, indoxyl sulfate and p-cresol sulfate) induce subclinical inflammatory processes involved in MetS. Gut microbiota’s taxonomic species or abundance are modified by many factors, including diet, lifestyle and medications. The main purpose of this review is to highlight the correlation between different dietary strategies and changes in gut microbiota metabolites. We mainly focus on the validity/inadequacy of specific dietary patterns to reduce inflammatory processes, including leaky gut and subsequent endotoxemia. We also describe the chance of probiotic supplementation to interact with the immune system and limit negative consequences associated with MetS.
Collapse
Affiliation(s)
| | | | - Valeria Gasperi
- Correspondence: (V.G.); (M.V.C.); Tel.: +39-06-72596465 (V.G. & M.V.C.)
| | | | | |
Collapse
|
85
|
Probiotic Supplement Preparation Relieves Test Anxiety by Regulating Intestinal Microbiota in College Students. DISEASE MARKERS 2021; 2021:5597401. [PMID: 33981369 PMCID: PMC8087991 DOI: 10.1155/2021/5597401] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Revised: 03/18/2021] [Accepted: 04/07/2021] [Indexed: 12/14/2022]
Abstract
Test anxiety creates barriers to learning and performance, which further affects students' social, behavioural, and emotional development. Currently, the medication to treat test anxiety has not been reported yet. Here, we enrolled 120 students to evaluate the effect of probiotic supplement preparation (PSP) on test anxiety from the aspect of the intestinal microbiota. We found that the intake of PSP alleviated the symptoms of depression and anxiety in students with test anxiety by evaluating their mental state using the Hamilton Depression Rating Scale and Hamilton Anxiety Scale. High-throughput sequencing results indicated that the consumption of PSP increased the abundance of Streptococcus and Akkermansia that was lowered by the anxiety state in the intestinal microbiota of students. Meanwhile, taking PSP reduced the level of intestinal pathogens of Fusobacterium and Clostridium as well. In conclusion, our work shows that PSP can reduce test anxiety and restore the disturbed microbiota to the standard level in Chinese college students, rendering the use of PSP a promising strategy for test anxiety.
Collapse
|
86
|
Bocanegra A, Macho-González A, Garcimartín A, Benedí J, Sánchez-Muniz FJ. Whole Alga, Algal Extracts, and Compounds as Ingredients of Functional Foods: Composition and Action Mechanism Relationships in the Prevention and Treatment of Type-2 Diabetes Mellitus. Int J Mol Sci 2021; 22:3816. [PMID: 33917044 PMCID: PMC8067684 DOI: 10.3390/ijms22083816] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 04/02/2021] [Accepted: 04/03/2021] [Indexed: 12/12/2022] Open
Abstract
Type-2 diabetes mellitus (T2DM) is a major systemic disease which involves impaired pancreatic function and currently affects half a billion people worldwide. Diet is considered the cornerstone to reduce incidence and prevalence of this disease. Algae contains fiber, polyphenols, ω-3 PUFAs, and bioactive molecules with potential antidiabetic activity. This review delves into the applications of algae and their components in T2DM, as well as to ascertain the mechanism involved (e.g., glucose absorption, lipids metabolism, antioxidant properties, etc.). PubMed, and Google Scholar databases were used. Papers in which whole alga, algal extracts, or their isolated compounds were studied in in vitro conditions, T2DM experimental models, and humans were selected and discussed. This review also focuses on meat matrices or protein concentrate-based products in which different types of alga were included, aimed to modulate carbohydrate digestion and absorption, blood glucose, gastrointestinal neurohormones secretion, glycosylation products, and insulin resistance. As microbiota dysbiosis in T2DM and metabolic alterations in different organs are related, the review also delves on the effects of several bioactive algal compounds on the colon/microbiota-liver-pancreas-brain axis. As the responses to therapeutic diets vary dramatically among individuals due to genetic components, it seems a priority to identify major gene polymorphisms affecting potential positive effects of algal compounds on T2DM treatment.
Collapse
Affiliation(s)
- Aránzazu Bocanegra
- Pharmacology, Pharmacognosy and Botany Department, Pharmacy School, Complutense University of Madrid, 28040 Madrid, Spain; (A.G.); (J.B.)
| | - Adrián Macho-González
- Nutrition and Food Science Department (Nutrition), Pharmacy School, Complutense University of Madrid, 28040 Madrid, Spain;
- AFUSAN Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC), 28040 Madrid, Spain
| | - Alba Garcimartín
- Pharmacology, Pharmacognosy and Botany Department, Pharmacy School, Complutense University of Madrid, 28040 Madrid, Spain; (A.G.); (J.B.)
- AFUSAN Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC), 28040 Madrid, Spain
| | - Juana Benedí
- Pharmacology, Pharmacognosy and Botany Department, Pharmacy School, Complutense University of Madrid, 28040 Madrid, Spain; (A.G.); (J.B.)
- AFUSAN Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC), 28040 Madrid, Spain
| | - Francisco José Sánchez-Muniz
- Nutrition and Food Science Department (Nutrition), Pharmacy School, Complutense University of Madrid, 28040 Madrid, Spain;
- AFUSAN Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC), 28040 Madrid, Spain
| |
Collapse
|
87
|
Wang L, Cheng R, Sun X, Zhao Y, Ge W, Yang Y, Gao Y, Ding Z, Liu J, Zhang J. Preparation and Gut Microbiota Modulatory Property of the Oligosaccharide Riclinoctaose. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2021; 69:3667-3676. [PMID: 33750134 DOI: 10.1021/acs.jafc.0c07783] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
In relation to available polysaccharides, oligosaccharides have a low molecular weight, less viscosity, and complete water solubility. These properties endow oligosaccharides with significant biological properties including the microbiota regulation ability. In this study, a homogeneous oligooctasaccharide, riclinoctaose, was biosynthesized from succinylglycan riclin by enzymatic degradation. Monosaccharide composition, Fourier-transform infrared, electrospray ionization mass spectrometry, and nuclear magnetic resonance spectrometry analysis indicated that riclinoctaose is an oligooctasaccharide consisting of one galactose and seven glucose residues, with a pyruvate group linked to the terminal glucose residue. The effects of dietary riclinoctaose on the gut microbiota of mice were evaluated. We found that the dietary riclinoctaose significantly altered intestinal microbiota with the increased growth of beneficial intestinal bacteria including Bifidobacteria and Lactobacillus and decreased the abundance of pernicious bacteria such as Gammaproteobacteria. The level of short-chain fatty acids (SCFAs) was significantly elevated in the riclinoctaose cecum. Our results suggested that riclinoctaose as a prebiotic may have a great potential application in functional foods.
Collapse
Affiliation(s)
- Lei Wang
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Rui Cheng
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Xiaqing Sun
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Yang Zhao
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Wenhao Ge
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Yunxia Yang
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Yan Gao
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Zhao Ding
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Junhao Liu
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| | - Jianfa Zhang
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
| |
Collapse
|
88
|
Tagliamonte S, Laiola M, Ferracane R, Vitale M, Gallo MA, Meslier V, Pons N, Ercolini D, Vitaglione P. Mediterranean diet consumption affects the endocannabinoid system in overweight and obese subjects: possible links with gut microbiome, insulin resistance and inflammation. Eur J Nutr 2021; 60:3703-3716. [PMID: 33763720 PMCID: PMC8437855 DOI: 10.1007/s00394-021-02538-8] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Accepted: 03/08/2021] [Indexed: 02/07/2023]
Abstract
Purpose To investigate whether a Mediterranean diet (MD) affected the plasma concentrations of endocannabinoids (ECs), N-acylethanolamines (NAEs) and their specific ratios in subjects with lifestyle risk factors for metabolic diseases. To identify the relationship between circulating levels of these compounds and gut microbiome, insulin resistance and systemic inflammation. Methods A parallel 8-week randomised controlled trial was performed involving 82 overweight and obese subjects aged (mean ± SEM) 43 ± 1.4 years with a BMI of 31.1 ± 0.5 kg/m2, habitual Western diet (CT) and sedentary lifestyle. Subjects were randomised to consume an MD tailored to their habitual energy and macronutrient intake (n = 43) or to maintain their habitual diet (n = 39). Endocannabinoids and endocannabinoid-like molecules, metabolic and inflammatory markers and gut microbiome were monitored over the study period. Results The MD intervention lowered plasma arachidonoylethanolamide (AEA, p = 0.02), increased plasma oleoylethanolamide/palmitoylethanolamide (OEA/PEA, p = 0.009) and OEA/AEA (p = 0.006) and increased faecal Akkermansia muciniphila (p = 0.026) independent of body weight changes. OEA/PEA positively correlated with abundance of key microbial players in diet–gut–health interplay and MD adherence. Following an MD, individuals with low-plasma OEA/PEA at baseline decreased homeostatic model assessment of insulin resistance index (p = 0.01), while individuals with high-plasma OEA/PEA decreased serum high-sensitive C-reactive protein (p = 0.02). Conclusions We demonstrated that a switch from a CT to an isocaloric MD affects the endocannabinoid system and increases A. muciniphila abundance in the gut independently of body weight changes. Endocannabinoid tone and microbiome functionality at baseline drives an individualised response to an MD in ameliorating insulin sensitivity and inflammation. Clinical Trial Registry number and website NCT03071718; www.clinicaltrials.gov Supplementary Information The online version contains supplementary material available at 10.1007/s00394-021-02538-8.
Collapse
Affiliation(s)
- Silvia Tagliamonte
- Department of Agricultural Sciences, University of Naples Federico II, Parco Gussone Ed. 84, 80055, Portici, NA), Italy
| | - Manolo Laiola
- Department of Agricultural Sciences, University of Naples Federico II, Parco Gussone Ed. 84, 80055, Portici, NA), Italy
| | - Rosalia Ferracane
- Department of Agricultural Sciences, University of Naples Federico II, Parco Gussone Ed. 84, 80055, Portici, NA), Italy
| | - Marilena Vitale
- Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131, Naples, Italy
| | | | - Victoria Meslier
- Université Paris-Saclay, INRAE (Institut National de Recherche Pour L'agriculture, l'alimentation Et L'environnement), MGP (Metagenopolis), 78350, Jouy en Josas, France
| | - Nicolas Pons
- Université Paris-Saclay, INRAE (Institut National de Recherche Pour L'agriculture, l'alimentation Et L'environnement), MGP (Metagenopolis), 78350, Jouy en Josas, France
| | - Danilo Ercolini
- Department of Agricultural Sciences, University of Naples Federico II, Parco Gussone Ed. 84, 80055, Portici, NA), Italy.,Task Force On Microbiome Studies, University of Naples Federico II, 80134, Naples, Italy
| | - Paola Vitaglione
- Department of Agricultural Sciences, University of Naples Federico II, Parco Gussone Ed. 84, 80055, Portici, NA), Italy. .,Task Force On Microbiome Studies, University of Naples Federico II, 80134, Naples, Italy.
| |
Collapse
|
89
|
Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients. J Pers Med 2021; 11:jpm11030238. [PMID: 33807075 PMCID: PMC8004607 DOI: 10.3390/jpm11030238] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 03/20/2021] [Accepted: 03/22/2021] [Indexed: 02/06/2023] Open
Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD) remains an important health issue worldwide. The increasing prevalence of NAFLD is linked to type 2 diabetes (T2D). The gut microbiota is associated with the development of NAFLD and T2D. However, the relationship between gut microbiota and NAFLD severity has remained unclear in T2D patients. The aim of this study was to evaluate the relationship of gut microbiota with the severity of NAFLD in T2D patients. Methods: This cross-sectional study used transient elastography (FibroScan) to evaluate the severity of hepatic steatosis. We utilized qPCR to measure the abundance of Bacteroidetes, Firmicutes, Faecalibacterium prausnitzii, Clostridium leptum group, Bacteroides, Bifidobacterium, Akkermansia muciniphila, and Escherichia coli. Results: Of 163 T2D patients, 83 with moderate to severe NAFLD had higher abundance of bacteria of the phylum Firmicutes with respect to 80 patients without NAFLD or with mild NAFLD. High abundance of the phylum Firmicutes increased the severity of NAFLD in T2D patients. A positive correlation between NAFLD severity and the phylum Firmicutes was found in T2D male patients with body mass index ≥24 kg/m2 and glycated hemoglobin <7.5%. Conclusion: Enrichment of the fecal microbiota with the phylum Firmicutes is significantly and positively associated with NAFLD severity in T2D patients. The gut microbiota is a potential predictor of NAFLD severity in T2D patients.
Collapse
|
90
|
Oh JH, Lee JH, Cho MS, Kim H, Chun J, Lee JH, Yoon Y, Kang W. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. Nutrients 2021; 13:nu13031013. [PMID: 33801023 PMCID: PMC8004024 DOI: 10.3390/nu13031013] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Revised: 03/16/2021] [Accepted: 03/19/2021] [Indexed: 12/12/2022] Open
Abstract
Metabolic associated fatty liver disease (MAFLD) is a new concept where the presence of both fatty liver and metabolic abnormality are necessary for diagnosis. Several studies have reported that altered gut microbiome is closely associated with metabolic diseases and non-alcoholic fatty liver disease. However, the studies on MAFLD population are scarce. This prospective study aimed to identify differences in gut microbiome between patients with MAFLD and healthy controls in Korean population. In this study, patients with MAFLD and age, sex-matched healthy controls were included, and their stool samples were collected. Taxonomic composition of gut microbiota was analyzed using 16S ribosomal ribonucleic acid pyrosequencing. Twenty-two MAFLD patients and 44 healthy controls were included. Taxonomic diversity was lower in patients with MAFLD in the aspect of alpha and beta diversity. The differences were also found at phylum, class, family, and genus levels between the two groups. Phylum Proteobacteria, family Enterobactereriaceae, genus Citrobacter abundance was significantly increased and genus Faecalibacterium was significantly decreased in patients with MAFLD. In addition, butyrate-producing bacteria were decreased and ethanol-producing bacteria were increased in patients with MAFLD. The composition of gut microbiome was different between MAFLD and healthy controls in Korean population. This could offer potential targets for therapeutic intervention in MAFLD.
Collapse
Affiliation(s)
- Joo Hyun Oh
- Samsung Medical Center, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; (J.H.O.); (J.H.L.)
- Department of Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul 01830, Korea
| | - Je Hee Lee
- ChunLab, Inc., Seoul 06194, Korea; (J.H.L.); (M.S.C.); (J.C.)
| | - Min Seok Cho
- ChunLab, Inc., Seoul 06194, Korea; (J.H.L.); (M.S.C.); (J.C.)
| | - Hyeree Kim
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul 06355, Korea;
- Samsung Medical Center, Institute for Future Medicine, Seoul 06351, Korea
| | - Jongsik Chun
- ChunLab, Inc., Seoul 06194, Korea; (J.H.L.); (M.S.C.); (J.C.)
| | - Joon Hyeok Lee
- Samsung Medical Center, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; (J.H.O.); (J.H.L.)
| | - Yeup Yoon
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul 06355, Korea;
- Samsung Medical Center, Institute for Future Medicine, Seoul 06351, Korea
- Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Korea
- Correspondence: (Y.Y.); (W.K.)
| | - Wonseok Kang
- Samsung Medical Center, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; (J.H.O.); (J.H.L.)
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul 06355, Korea;
- Samsung Medical Center, Institute for Future Medicine, Seoul 06351, Korea
- Correspondence: (Y.Y.); (W.K.)
| |
Collapse
|
91
|
Corb Aron RA, Abid A, Vesa CM, Nechifor AC, Behl T, Ghitea TC, Munteanu MA, Fratila O, Andronie-Cioara FL, Toma MM, Bungau S. Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a Key Gut Bacterium. Microorganisms 2021; 9:microorganisms9030618. [PMID: 33802777 PMCID: PMC8002498 DOI: 10.3390/microorganisms9030618] [Citation(s) in RCA: 68] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 03/09/2021] [Accepted: 03/15/2021] [Indexed: 12/14/2022] Open
Abstract
Metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) are diseases that can be influenced by the structure of gut microbiota, whose improvement is often neglected in metabolic pathology. This review highlights the following main aspects: the relationship between probiotics/gut microbes with the pathogenesis of MetS, the particular positive roles of Akkermansia muciniphila supplementation in the onset of MetS, and the interaction between dietary polyphenols (prebiotics) with gut microbiota. Therefore, an extensive and in-depth analysis of the often-neglected correlation between gut microbiota and chronic metabolic diseases was conducted, considering that this topic continues to fascinate and stimulate researchers through the discovery of novel strains and their beneficial properties.
Collapse
Affiliation(s)
- Raluca Anca Corb Aron
- Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania; (R.A.C.A.); (C.M.V.)
| | - Areha Abid
- Department of Food Science, Faculty of Agricultural and Food Sciences, University of Debrecen, 4032 Debrecen, Hungary;
| | - Cosmin Mihai Vesa
- Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania; (R.A.C.A.); (C.M.V.)
| | - Aurelia Cristina Nechifor
- Department of Analytical Chemistry, Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, 011061 Bucharest, Romania;
| | - Tapan Behl
- Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India;
| | - Timea Claudia Ghitea
- Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania; (T.C.G.); (M.M.T.)
| | - Mihai Alexandru Munteanu
- Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania; (M.A.M.); (O.F.)
| | - Ovidiu Fratila
- Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania; (M.A.M.); (O.F.)
| | - Felicia Liana Andronie-Cioara
- Department of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania;
| | - Mirela Marioara Toma
- Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania; (T.C.G.); (M.M.T.)
| | - Simona Bungau
- Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania; (T.C.G.); (M.M.T.)
- Correspondence: ; Tel.: +40-726-776-588
| |
Collapse
|
92
|
Breuninger TA, Wawro N, Breuninger J, Reitmeier S, Clavel T, Six-Merker J, Pestoni G, Rohrmann S, Rathmann W, Peters A, Grallert H, Meisinger C, Haller D, Linseisen J. Associations between habitual diet, metabolic disease, and the gut microbiota using latent Dirichlet allocation. MICROBIOME 2021; 9:61. [PMID: 33726846 PMCID: PMC7967986 DOI: 10.1186/s40168-020-00969-9] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Accepted: 12/06/2020] [Indexed: 06/10/2023]
Abstract
BACKGROUND The gut microbiome impacts human health through various mechanisms and is involved in the development of a range of non-communicable diseases. Diet is a well-known factor influencing microbe-host interaction in health and disease. However, very few findings are based on large-scale analysis using population-based studies. Our aim was to investigate the cross-sectional relationship between habitual dietary intake and gut microbiota structure in the Cooperative Health Research in the Region of Augsburg (KORA) FF4 study. RESULTS Fecal microbiota was analyzed using 16S rRNA gene amplicon sequencing. Latent Dirichlet allocation (LDA) was applied to samples from 1992 participants to identify 20 microbial subgroups within the study population. Each participant's gut microbiota was subsequently described by a unique composition of these 20 subgroups. Associations between habitual dietary intake, assessed via repeated 24-h food lists and a Food Frequency Questionnaire, and the 20 subgroups, as well as between prevalence of metabolic diseases/risk factors and the subgroups, were assessed with multivariate-adjusted Dirichlet regression models. After adjustment for multiple testing, eight of 20 microbial subgroups were significantly associated with habitual diet, while nine of 20 microbial subgroups were associated with the prevalence of one or more metabolic diseases/risk factors. Subgroups 5 (Faecalibacterium, Lachnospiracea incertae sedis, Gemmiger, Roseburia) and 14 (Coprococcus, Bacteroides, Faecalibacterium, Ruminococcus) were particularly strongly associated with diet. For example, participants with a high probability for subgroup 5 were characterized by a higher Alternate Healthy Eating Index and Mediterranean Diet Score and a higher intake of food items such as fruits, vegetables, legumes, and whole grains, while participants with prevalent type 2 diabetes mellitus were characterized by a lower probability for subgroup 5. CONCLUSIONS The associations between habitual diet, metabolic diseases, and microbial subgroups identified in this analysis not only expand upon current knowledge of diet-microbiota-disease relationships, but also indicate the possibility of certain microbial groups to be modulated by dietary intervention, with the potential of impacting human health. Additionally, LDA appears to be a powerful tool for interpreting latent structures of the human gut microbiota. However, the subgroups and associations observed in this analysis need to be replicated in further studies. Video abstract.
Collapse
Affiliation(s)
- Taylor A. Breuninger
- Independent Research Unit Clinical Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
- Ludwig-Maximilians-Universität München, UNIKA-T Augsburg, Neusässer Str. 47, 86156 Augsburg, Germany
| | - Nina Wawro
- Independent Research Unit Clinical Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
- Ludwig-Maximilians-Universität München, UNIKA-T Augsburg, Neusässer Str. 47, 86156 Augsburg, Germany
| | | | - Sandra Reitmeier
- Technische Universität München, Gregor-Mendel-Str. 2, 85354 Freising, Germany
- ZIEL - Institute for Food & Health, Technische Universität München, Weihenstephaner Berg 3, 85354 Freising, Germany
| | - Thomas Clavel
- ZIEL - Institute for Food & Health, Technische Universität München, Weihenstephaner Berg 3, 85354 Freising, Germany
- Functional Microbiome Research Group, Institute of Medical Microbiology, RWTH University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany
| | - Julia Six-Merker
- Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
| | - Giulia Pestoni
- Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, CH-8001 Zurich, Switzerland
| | - Sabine Rohrmann
- Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, CH-8001 Zurich, Switzerland
| | - Wolfgang Rathmann
- Institute for Biometrics and Epidemiology, Deutsches Diabetes-Zentrum (DDZ), Auf’m Hennekamp 65, 40225 Düsseldorf, Germany
| | - Annette Peters
- Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
| | - Harald Grallert
- Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
| | - Christa Meisinger
- Independent Research Unit Clinical Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
- Ludwig-Maximilians-Universität München, UNIKA-T Augsburg, Neusässer Str. 47, 86156 Augsburg, Germany
| | - Dirk Haller
- Technische Universität München, Gregor-Mendel-Str. 2, 85354 Freising, Germany
- ZIEL - Institute for Food & Health, Technische Universität München, Weihenstephaner Berg 3, 85354 Freising, Germany
| | - Jakob Linseisen
- Independent Research Unit Clinical Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
- Ludwig-Maximilians-Universität München, UNIKA-T Augsburg, Neusässer Str. 47, 86156 Augsburg, Germany
- ZIEL - Institute for Food & Health, Technische Universität München, Weihenstephaner Berg 3, 85354 Freising, Germany
| |
Collapse
|
93
|
Abstract
The substantial burden of colorectal cancer and its increasing trend in young adults highlight the importance of dietary and lifestyle modifications for improved cancer prevention and survivorship. In this chapter, we review the cutting-edge evidence for the interplay between diet/lifestyle and the gut microbiota in the incidence and prognosis of colorectal cancer. We focus on factors for which there are data supporting their importance for the gut microbiota and colorectal cancer, including excess body weight, fiber, red and processed meat, and coffee. We discuss the potential precision nutrition approaches for modifying and exploiting the gut microbiota for improved cancer prevention and survivorship.
Collapse
Affiliation(s)
- Kai Wang
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States
| | - Mingyang Song
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
| |
Collapse
|
94
|
Pinna NK, Anjana RM, Saxena S, Dutta A, Gnanaprakash V, Rameshkumar G, Aswath S, Raghavan S, Rani CSS, Radha V, Balasubramanyam M, Pant A, Nielsen T, Jørgensen T, Færch K, Kashani A, Silva MCA, Vestergaard H, Hansen TH, Hansen T, Arumugam M, Nair GB, Das B, Pedersen O, Mohan V, Mande SS. Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark. Genome Med 2021; 13:36. [PMID: 33658065 PMCID: PMC7931552 DOI: 10.1186/s13073-021-00851-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 02/11/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Recent studies have indicated an association of gut microbiota and microbial metabolites with type 2 diabetes mellitus (T2D). However, large-scale investigation of the gut microbiota of "prediabetic" (PD) subjects has not been reported. Identifying robust gut microbiome signatures of prediabetes and characterizing early prediabetic stages is important for the understanding of disease development and could be crucial in early diagnosis and prevention. METHODS The current study performed amplification and sequencing on the variable regions (V1-V5) of the 16S rRNA genes to profile and compare gut microbiota of prediabetic individuals (N = 262) with normoglycemic individuals (N = 275) from two cohorts in India and Denmark. Similarly, fasting serum inflammatory biomarkers were profiled from the study participants. RESULTS After correcting for strong country-specific cohort effect, 16 operational taxonomic units (OTUs) including members from the genera Prevotella9, Phascolarctobacterium, Barnesiella, Flavonifractor, Tyzzerella_4, Bacteroides, Faecalibacterium, and Agathobacter were identified as enriched in normoglycaemic subjects with respect to the subjects with prediabetes using a negative binomial Wald test. We also identified 144 OTUs enriched in the prediabetic subjects, which included members from the genera Megasphaera, Streptococcus, Prevotella9, Alistipes, Mitsuokella, Escherichia/Shigella, Prevotella2, Vibrio, Lactobacillus, Alloprevotella, Rhodococcus, and Klebsiella. Comparative analyses of relative abundance of bacterial taxa revealed that the Streptococcus, Escherichia/Shigella, Prevotella2, Vibrio, and Alloprevotella OTUs exhibited more than fourfold enrichment in the gut microbiota of prediabetic subjects. When considering subjects from the two geographies separately, we were able to identify additional gut microbiome signatures of prediabetes. The study reports a probable association of Megasphaera OTU(s) with impaired glucose tolerance, which is significantly pronounced in Indian subjects. While the overall results confirm a state of proinflammation as early as in prediabetes, the Indian cohort exhibited a characteristic pattern of abundance of inflammatory markers indicating low-grade intestinal inflammation at an overall population level, irrespective of glycemic status. CONCLUSIONS The results present trans-ethnic gut microbiome and inflammation signatures associated with prediabetes, in Indian and Danish populations. The identified associations may be explored further as potential early indicators for individuals at risk of dysglycemia.
Collapse
Affiliation(s)
- Nishal Kumar Pinna
- TCS Research, Tata Consultancy Services Limited, 54B Hadapsar Industrial Estate, Pune, 411013, India
| | - Ranjit Mohan Anjana
- Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
| | - Shruti Saxena
- Molecular Genetics Laboratory, Infections and Immunology, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO box #04, Faridabad, 121001, India
| | - Anirban Dutta
- TCS Research, Tata Consultancy Services Limited, 54B Hadapsar Industrial Estate, Pune, 411013, India
| | - Visvanathan Gnanaprakash
- Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
| | - Gnanavadivel Rameshkumar
- Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
| | - Sukumaran Aswath
- Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
| | - Srividhya Raghavan
- Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
| | | | - Venkatesan Radha
- Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
| | - Muthuswamy Balasubramanyam
- Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India.,Present address: SRM Medical College Hospital & Research Centre, SRM Institute of Science & Technology (SRMIST), Kattankulathur, Chennai, India
| | - Archana Pant
- Molecular Genetics Laboratory, Infections and Immunology, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO box #04, Faridabad, 121001, India
| | - Trine Nielsen
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Maersk Tower, Building: 07-8-55, DK-2200, Copenhagen N, Denmark
| | - Torben Jørgensen
- Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark
| | | | - Alireza Kashani
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Maersk Tower, Building: 07-8-55, DK-2200, Copenhagen N, Denmark.,Current affiliation: Qbiom, Microbiome Consultancy Service, Copenhagen, Denmark
| | - Maria Camila Alvarez Silva
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Maersk Tower, Building: 07-8-55, DK-2200, Copenhagen N, Denmark
| | - Henrik Vestergaard
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Maersk Tower, Building: 07-8-55, DK-2200, Copenhagen N, Denmark
| | - Tue Haldor Hansen
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Maersk Tower, Building: 07-8-55, DK-2200, Copenhagen N, Denmark.,Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Denmark
| | - Torben Hansen
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Maersk Tower, Building: 07-8-55, DK-2200, Copenhagen N, Denmark
| | - Manimozhiyan Arumugam
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Maersk Tower, Building: 07-8-55, DK-2200, Copenhagen N, Denmark
| | - Gopinath Balakrish Nair
- Molecular Genetics Laboratory, Infections and Immunology, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO box #04, Faridabad, 121001, India
| | - Bhabatosh Das
- Molecular Genetics Laboratory, Infections and Immunology, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO box #04, Faridabad, 121001, India.
| | - Oluf Pedersen
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Maersk Tower, Building: 07-8-55, DK-2200, Copenhagen N, Denmark.
| | - Viswanathan Mohan
- Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India.
| | - Sharmila Shekhar Mande
- TCS Research, Tata Consultancy Services Limited, 54B Hadapsar Industrial Estate, Pune, 411013, India.
| |
Collapse
|
95
|
Zhang Y, Zhu C, Cao G, Zhan J, Feng X, Chen X. Dynamic Alterations of Oral Microbiota Related to Halitosis in Preschool Children. Front Cell Infect Microbiol 2021; 11:599467. [PMID: 33718263 PMCID: PMC7952759 DOI: 10.3389/fcimb.2021.599467] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Accepted: 01/27/2021] [Indexed: 12/31/2022] Open
Abstract
Objective This longitudinal study was aimed to evaluate the dynamic shift in oral microbiota during the process of halitosis progression among preschool children. Methods The oral examinations, questionnaires and tongue coating specimens were collected at the baseline and 12-month follow-up. All children were oral healthy at the enrollment. At the 12-month follow-up, children who developed halitosis were included to the halitosis group (n = 10). While children who matched the age, gender, kindergarten and without halitosis were included to the control group (n = 10). 16S rRNA gene sequencing was used to reveal the shift of the tongue coating microbiome in these children during the 12- month period with the Human Oral Microbiome Database. Results A remarkable shift in relative abundance of specific bacteria was observed prior to halitosis development. The principal coordinates and alpha diversity analyses revealed different shifting patterns of halitosis and the healthy participants’ microbiome structures and bacterial diversity over the 12-month follow-up. Both groups showed variable microbiota community structures before the onset of halitosis. Halitosis-enriched species Prevotella melaninogenica, Actinomyces sp._HMT_180 and Saccharibacteria TM7_G-1_bacterium_HMT_352 were finally selected as biomarkers in the halitosis-onset prediction model after screening, with a prediction accuracy of 91.7%. Conclusions The microbiome composition and relative abundance of the tongue coatings in the halitosis and control groups remarkably differed, even prior to the onset of the clinical manifestations of halitosis. The halitosis prediction model constructed on the basis of tongue coating microbiome biomarkers indicated the microbial shifts before the halitosis onset. Therefore, this can be considered for the timely detection and intervention of halitosis in children.
Collapse
Affiliation(s)
- Yu Zhang
- Department of Preventive Dentistry, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai, China.,Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China
| | - Ce Zhu
- Department of Preventive Dentistry, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai, China.,Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China
| | - Guizhi Cao
- Department of Preventive Dentistry, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai, China.,Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China
| | - Jingyu Zhan
- Department of Preventive Dentistry, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai, China.,Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China
| | - Xiping Feng
- Department of Preventive Dentistry, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai, China.,Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China
| | - Xi Chen
- Department of Preventive Dentistry, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai, China.,Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China
| |
Collapse
|
96
|
Ngowi EE, Wang YZ, Khattak S, Khan NH, Mahmoud SSM, Helmy YASH, Jiang QY, Li T, Duan SF, Ji XY, Wu DD. Impact of the factors shaping gut microbiota on obesity. J Appl Microbiol 2021; 131:2131-2147. [PMID: 33570819 DOI: 10.1111/jam.15036] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 02/01/2021] [Accepted: 02/08/2021] [Indexed: 12/12/2022]
Abstract
Obesity is considered as a risk factor for chronic health diseases such as heart diseases, cancer and diabetes 2. Reduced physical activities, lifestyle, poor nutritional diet and genetics are among the risk factors associated with the development of obesity. In recent years, several studies have explored the link between the gut microbiome and the progression of diseases including obesity, with the shift in microbiome abundance and composition being the main focus. The alteration of gut microbiome composition affects both nutrients metabolism and specific gene expressions, thereby disturbing body physiology. Specifically, the abundance of fibre-metabolizing microbes is associated with weight loss and that of protein and fat-metabolizing bacteria with weight gain. Various internal and external factors such as genetics, maternal obesity, mode of delivery, breastfeeding, nutrition, antibiotic use and the chemical compounds present in the environment are known to interfere with the richness of the gut microbiota (GM), thus influencing weight gain/loss and ultimately the development of obesity. However, the effectiveness of each factor in potentiating the shift in microbes' abundance to result in significant changes that can lead to obesity is not yet clear. In this review, we will highlight the factors involved in shaping GM, their influence on obesity and possible interventions. Understanding the influence of these factors on the diversity of the GM and how to improve their effectiveness on disease conditions could be keys in the treatment of metabolic diseases.
Collapse
Affiliation(s)
- Ebenezeri Erasto Ngowi
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China.,Department of Biological Sciences, Faculty of Science, Dares Salaam University College of Education, Dares Salaam, Tanzania
| | - Yi-Zhen Wang
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China
| | - Saadullah Khattak
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China
| | - Nazeer Hussain Khan
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China
| | - Salma Sayed Mohamed Mahmoud
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China
| | - Yasmeen Ahmed Saleheldin Hassan Helmy
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China
| | - Qi-Ying Jiang
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China
| | - Tao Li
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China
| | - Shao-Feng Duan
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, Henan, China
| | - Xin-Ying Ji
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,Kaifeng Key Laboratory of Infection and Biological Safety, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China
| | - Dong-Dong Wu
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China.,School of Stomatology, Henan University, Kaifeng, Henan, China
| |
Collapse
|
97
|
Song Q, Wang Y, Huang L, Shen M, Yu Y, Yu Q, Chen Y, Xie J. Review of the relationships among polysaccharides, gut microbiota, and human health. Food Res Int 2021; 140:109858. [DOI: 10.1016/j.foodres.2020.109858] [Citation(s) in RCA: 79] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Revised: 09/18/2020] [Accepted: 10/26/2020] [Indexed: 12/20/2022]
|
98
|
Keleszade E, Patterson M, Trangmar S, Guinan KJ, Costabile A. Clinical Efficacy of Brown Seaweeds Ascophyllum nodosum and Fucus vesiculosus in the Prevention or Delay Progression of the Metabolic Syndrome: A Review of Clinical Trials. Molecules 2021; 26:714. [PMID: 33573121 PMCID: PMC7866543 DOI: 10.3390/molecules26030714] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 01/25/2021] [Accepted: 01/26/2021] [Indexed: 12/12/2022] Open
Abstract
Metabolic syndrome (MetS) is a global public health problem affecting nearly 25.9% of the world population characterised by a cluster of disorders dominated by abdominal obesity, high blood pressure, high fasting plasma glucose, hypertriacylglycerolaemia and low HDL-cholesterol. In recent years, marine organisms, especially seaweeds, have been highlighted as potential natural sources of bioactive compounds and useful metabolites, with many biological and physiological activities to be used in functional foods or in human nutraceuticals for the management of MetS and related disorders. Of the three groups of seaweeds, brown seaweeds are known to contain more bioactive components than either red and green seaweeds. Among the different brown seaweed species, Ascophyllum nodosum and Fucus vesiculosus have the highest antioxidant values and highest total phenolic content. However, the evidence base relies mainly on cell line and small animal models, with few studies to date involving humans. This review intends to provide an overview of the potential of brown seaweed extracts Ascophyllum nodosum and Fucus vesiculosus for the management and prevention of MetS and related conditions, based on the available evidence obtained from clinical trials.
Collapse
Affiliation(s)
- Enver Keleszade
- Department of Life Sciences, University of Roehampton, London SW15 4JD, UK; (E.K.); (M.P.); (S.T.)
| | - Michael Patterson
- Department of Life Sciences, University of Roehampton, London SW15 4JD, UK; (E.K.); (M.P.); (S.T.)
| | - Steven Trangmar
- Department of Life Sciences, University of Roehampton, London SW15 4JD, UK; (E.K.); (M.P.); (S.T.)
| | | | - Adele Costabile
- Department of Life Sciences, University of Roehampton, London SW15 4JD, UK; (E.K.); (M.P.); (S.T.)
| |
Collapse
|
99
|
Alvarez-Vieites E, López-Santamarina A, Miranda JM, Del Carmen Mondragón A, Lamas A, Cardelle-Cobas A, Nebot C, Franco CM, Cepeda A. Influence of the Intestinal Microbiota on Diabetes Management. Curr Pharm Biotechnol 2021; 21:1603-1615. [PMID: 32410561 DOI: 10.2174/1389201021666200514220950] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Revised: 03/01/2020] [Accepted: 03/10/2020] [Indexed: 11/22/2022]
Abstract
In recent decades, there has been a very rapid increase in the prevalence of diabetes globally, with serious health and economic implications. Although today there are several therapeutic treatments for this disease, these do not address the causes of the disease and have serious side effects, so it is necessary to seek new treatments to replace or complement the existing ones. Among these complementary treatments, a strong link between the intestinal microbiota and diabetes has been demonstrated, which has focused attention on the use of biotherapy to regulate the function of the intestinal microbiota and, thus, treat diabetes. In this way, the main objective of this work is to provide a review of the latest scientific evidence on diabetes, gathering information about new trends in its management, and especially, the influence of the intestinal microbiota and microbiome on this pathology. It is possible to conclude that the relationship between the intestinal microbiota and diabetes is carried out through alterations in energy metabolism, the immune system, changes in intestinal permeability, and a state of low-intensity systemic inflammation. Although, currently, most of the experimental work, using probiotics for diabetes management, has been done on experimental animals, the results obtained are promising. Thus, the modification of the microbiota through biotherapy has shown to improve the symptoms and severity of diabetes through various mechanisms related to these alterations.
Collapse
Affiliation(s)
- Eva Alvarez-Vieites
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| | - Arora López-Santamarina
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| | - José M Miranda
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| | - Alicia Del Carmen Mondragón
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| | - Alexandre Lamas
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| | - Alejandra Cardelle-Cobas
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| | - Carolina Nebot
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| | - Carlos M Franco
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| | - Alberto Cepeda
- Laboratorio de Higiene Inspeccion y Control de Alimentos, Departamento de Quimica Analitica, Nutricion y Bromatologia, Universidad de Santiago de Compostela, 27002-Lugo, Spain
| |
Collapse
|
100
|
Jia R, Huang M, Qian L, Yan X, Lv Q, Ye H, Ye L, Wu X, Chen W, Chen Y, Jia Y, Huang Y, Wu H. The Depletion of Carbohydrate Metabolic Genes in the Gut Microbiome Contributes to the Transition From Central Obesity to Type 2 Diabetes. Front Endocrinol (Lausanne) 2021; 12:747646. [PMID: 34745012 PMCID: PMC8569854 DOI: 10.3389/fendo.2021.747646] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Accepted: 09/21/2021] [Indexed: 12/12/2022] Open
Abstract
Obesity, especially central obesity, is a strong risk factor for developing type 2 diabetes (T2D). However, the mechanism underlying the progression from central obesity to T2D remains unknown. Therefore, we analyzed the gut microbial profiles of central obese individuals with or without T2D from a Chinese population. Here we reported both the microbial compositional and gene functional alterations during the progression from central obesity to T2D. Several opportunistic pathogens were enriched in obese T2D patients. We also characterized thousands of genes involved in sugar and amino acid metabolism whose abundance were significantly depleted in obese T2D group. Moreover, the abundance of those genes was negatively associated with plasma glycemia level and percentage of individuals with impaired plasma glucose status. Therefore, our study indicates that the abundance of those depleted genes can be used as a potential biomarker to identify central obese individuals with high risks of developing T2D.
Collapse
MESH Headings
- Adult
- Biomarkers/metabolism
- Carbohydrate Metabolism/genetics
- Case-Control Studies
- China
- Diabetes Mellitus, Type 2/etiology
- Diabetes Mellitus, Type 2/genetics
- Diabetes Mellitus, Type 2/metabolism
- Diabetes Mellitus, Type 2/microbiology
- Disease Progression
- Disease Susceptibility
- Female
- Gastrointestinal Microbiome/genetics
- Humans
- Male
- Metagenome/physiology
- Obesity, Abdominal/genetics
- Obesity, Abdominal/metabolism
- Obesity, Abdominal/microbiology
- Obesity, Abdominal/pathology
- RNA, Ribosomal, 16S/analysis
- RNA, Ribosomal, 16S/genetics
- Risk Factors
- Transcriptome
Collapse
Affiliation(s)
| | - Min Huang
- Department of General Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
| | | | - Xiaoye Yan
- Department of General Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
| | - Qing Lv
- Department of General Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
| | - Hua Ye
- GENEWIZ Inc., Suzhou, China
| | - Li Ye
- GENEWIZ Inc., Suzhou, China
| | - Xin Wu
- GENEWIZ Inc., Suzhou, China
| | | | | | | | - Yueqing Huang
- Department of General Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
- *Correspondence: Yueqing Huang, ; Huihui Wu,
| | - Huihui Wu
- GENEWIZ Inc., Suzhou, China
- *Correspondence: Yueqing Huang, ; Huihui Wu,
| |
Collapse
|